Camptothecin
Based on 68 publication(s) in Google Scholar
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 7689-03-4
- Formula: C20H16N2O4
- Molecular Weight:348.35
-
Storage:
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications Citing Use of MedChemExpress (MCE) Camptothecin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Cancer Cell. 2025 Feb 10;43(2):269-291.e19. [Abstract]
- Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
- Mol Cancer. 2025 Oct 21;24(1):263. [Abstract]
- Nat Immunol. 2024 Apr;25(4):659-670. [Abstract]
- Immunity. 2022 Aug 9;55(8):1370-1385.e8. [Abstract]
- Mol Cell. 2025 Jul 17;85(14):2654-2672.e7. [Abstract]
- Cancer Res. 2025 May 14. [Abstract]
- ACS Nano. 2024 Mar 19;18(11):8337-8349. [Abstract]
- Nat Commun. 2025 Mar 6;16(1):2239. [Abstract]
- Nat Commun. 2024 Sep 27;15(1):8283. [Abstract]
- Nat Commun. 2022 Aug 16;13(1):4822. [Abstract]
- Nat Commun. 2021 Aug 16;12(1):4961. [Abstract]
- Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
- Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]
- Cell Death Differ. 2025 Jul;32(7):1317-1335. [Abstract]
- Cell Death Differ. 2025 Apr;32(4):672-688. [Abstract]
- Cell Death Differ. 2020 Nov;27(11):3162-3176. [Abstract]
- Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(23):e11485. [Abstract]
- Cancer Lett. 2022 Oct 28:547:215855. [Abstract]
- Int J Biol Sci. 2015 Aug 8;11(10):1181-9. [Abstract]
- Gene Dis. 2019 May 25;7(3):401-407. [Abstract]
- Proc Natl Acad Sci U S A. 2023 May 16;120(20):e2303479120. [Abstract]
- J Transl Med. 2016 Mar 15:14:73. [Abstract]
- Oncogene. 2023 Mar;42(13):967-979. [Abstract]
- PLoS Biol. 2022 Feb 24;20(2):e3001517. [Abstract]
- Cell Rep. 2025 Aug 12;44(8):116152. [Abstract]
- Cell Rep. 2024 Feb 13;43(2):113779. [Abstract]
- J Med Chem. 2025 Mar 27;68(6):6339-6360. [Abstract]
- J Cell Biol. 2026 Jan 5;225(1):e202501091. [Abstract]
- Int J Mol Med. 2019 Jun;43(6):2491-2498. [Abstract]
- Cells. 2019 Oct 15;8(10):1258. [Abstract]
- Int J Mol Sci. 2025 Feb 25;26(5):1987. [Abstract]
- Int Immunopharmacol. 2026 Jan 31:173:116284. [Abstract]
- Eur J Pharmacol. 2026 Jan 12:1011:178422. [Abstract]
- Front Endocrinol. 2022 Jun 16:13:912648. [Abstract]
- Cancers (Basel). 2023 Sep 6;15(18):4442. [Abstract]
- FASEB J. 2026 Jan 31;40(2):e71434. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Transl Oncol. 2026 Apr:66:102701. [Abstract]
- J Inflamm Res. 2025 Mar 20:18:4213-4231. [Abstract]
- J Cell Physiol. 2019 Mar;234(3):2683-2692. [Abstract]
- PLoS Genet. 2019 Feb 4;15(2):e1007925. [Abstract]
- Exp Cell Res. 2020 Sep 15;394(2):112148. [Abstract]
- BMC Cancer. 2025 Feb 8;25(1):223. [Abstract]
- BMC Cancer. 2024 Mar 9;24(1):326. [Abstract]
- Cell Biol Int. 2020 Aug;44(8):1640-1650. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Toxicol In Vitro. 2020 Jun;65:104825. [Abstract]
- Toxicol In Vitro. 2017 Aug:42:130-138. [Abstract]
- J Hum Genet. 2025 Feb;70(2):87-97. [Abstract]
- Exp Ther Med. 2021 May;21(5):505. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- Biomed Chromatogr. 2025 Nov;39(11):e70237. [Abstract]
- Biosci Biotechnol Biochem. 2022 Jan 24;86(2):224-230. [Abstract]
- bioRxiv. 2025 Sep 21.
- bioRxiv. 2025 Aug 06.
- bioRxiv. 2025 Aug 19.
- SSRN. 2025 Jul 26.
- bioRxiv. 2025 Mar 10:2025.03.07.642025. [Abstract]
- bioRxiv. 2024 Sep 24:2024.09.23.614588. [Abstract]
- bioRxiv. 2023 Sep 28:2023.09.28.559973. [Abstract]
- Arch Cancer Res. 2023 Jan 30.
- bioRxiv. January 25, 2022.
- Health Science Journal. August 31, 2021.
- Patent. US20210009719A1.
- bioRxiv. 2019 Apr.
-
Cell Proliferation/Viability Assay
-
IP
-
IF
-
WB
All Topoisomerase Isoforms
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Topoisomerase I 679 nM (IC50) |
Camptothecins |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 184B5 | IC50 |
4.96 μM
Compound: Camptothecin
|
Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay
Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| 1A9 | ED50 |
3.2 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| 4T1 | IC50 |
0.17 μM
Compound: 1; CPT
|
Antiproliferative activity against mouse 4T1 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse 4T1 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| 4T1 | IC50 |
>300 μM
Compound: CPT
|
Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| 786-0 | IC50 |
0.015 μM
Compound: CPT
|
Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| 833K | IC50 |
10 nM
Compound: CPT
|
Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
|
10.1016/S0960-894X(97)10181-0 |
| A 172 | IC50 |
0.14 μM
Compound: CPT ((S)-Camptothecin)
|
Cytotoxicity against A-172 human tumor cell lines
Cytotoxicity against A-172 human tumor cell lines
|
10.1016/0960-894X(96)00131-X |
| A 172 | IC50 |
0.14 μM
Compound: 13 ((S)-CPT, Camptothecin)
|
In vitro cytotoxicity against A172 human tumor cell lines.
In vitro cytotoxicity against A172 human tumor cell lines.
|
10.1016/0960-894X(96)00132-1 |
| A20 | IC50 |
179.2 μM
Compound: CPT
|
Cytostatic activity against mouse A20 cells after 24 hrs by CCK-8 assay
Cytostatic activity against mouse A20 cells after 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| A2780 | IC50 |
0.004 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells after 72 hrs by MTS method
Cytotoxicity against human A2780 cells after 72 hrs by MTS method
|
[PMID: 11858737] |
| A2780 | IC50 |
0.007 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against A2780 (human ovarian cancer)
In vitro cytotoxicity against A2780 (human ovarian cancer)
|
[PMID: 14552770] |
| A2780 | IC50 |
0.07 μg/mL
Compound: camptothecin
|
Cytotoxicity against human A2780 cells by clonogenic assay
Cytotoxicity against human A2780 cells by clonogenic assay
|
[PMID: 16499333] |
| A2780 | IC50 |
0.28 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 18095653] |
| A2780 | IC50 |
0.2 μM
Compound: 1, CPT
|
Cytotoxicity against human A2780 cells after 4 days by MTT assay
Cytotoxicity against human A2780 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| A2780 | IC50 |
0.3 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 19256478] |
| A2780 | IC50 |
0.28 μM
Compound: Camptothecin
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 19453174] |
| A2780 | GI50 |
0.46 μM
Compound: CPT
|
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| A2780 | IC50 |
0.3 μM
Compound: CPT
|
Cytotoxicity against human A2780 cells after 4 days by MTT assay
Cytotoxicity against human A2780 cells after 4 days by MTT assay
|
[PMID: 19702283] |
| A2780 | IC50 |
0.28 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 19916529] |
| A2780 | IC50 |
0.2 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
|
[PMID: 20961093] |
| A2780 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 22044245] |
| A2780 | IC50 |
7 nM
Compound: Cpt
|
Cytotoxicity against human A2780 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 22749423] |
| A2780 | IC50 |
13 nM
Compound: CPT
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| A2780 | IC50 |
0.9 μM
Compound: camptothecin
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 25237727] |
| A2780 | IC50 |
0.029 μM
Compound: 1; CPT
|
Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay
Antiproliferative activity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 27871039] |
| A-375 | IC50 |
0.187 μM
Compound: CPT, Camptothecin
|
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
|
[PMID: 24980118] |
| A-375 | IC50 |
0.013 μM
Compound: Camptothecin
|
Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
|
[PMID: 27096049] |
| A-375 | IC50 |
0.66 μM
Compound: CPT
|
Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| A-427 | IC50 |
24 nM
Compound: CPT
|
Antiproliferative activity measured against A427 human lung carcinoma
Antiproliferative activity measured against A427 human lung carcinoma
|
[PMID: 9876111] |
| A-431 | IC50 |
0.011 μM
Compound: 1, CPT
|
Cytotoxicity against human A431 cells after 72 hrs by trypan blue assay
Cytotoxicity against human A431 cells after 72 hrs by trypan blue assay
|
[PMID: 21071230] |
| A549 | IC50 |
330 μM
Compound: C (20)(S)-1
|
In vitro cytotoxicity against human tumor cell line A549
In vitro cytotoxicity against human tumor cell line A549
|
[PMID: 10576688] |
| A549 | IC50 |
67 nM
Compound: CPT
|
Cytotoxicity against A549 tumor cell line determined by WST-1 assay
Cytotoxicity against A549 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| A549 | IC50 |
14 nM
Compound: CPT
|
In Vitro cytotoxicity against human lung cancer cell line (A549)
In Vitro cytotoxicity against human lung cancer cell line (A549)
|
[PMID: 11334569] |
| A549 | IC50 |
4 μM
Compound: Camptothecin
|
Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
|
[PMID: 11430001] |
| A549 | IC50 |
2.53 μM
Compound: Camptothecin
|
In vitro antiproliferative activity of compound against AS-49 (human lung caner ) cell line was determined by SRB assay
In vitro antiproliferative activity of compound against AS-49 (human lung caner ) cell line was determined by SRB assay
|
[PMID: 12639541] |
| A549 | IC50 |
0.008 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against A549 (human lung cancer)
In vitro cytotoxicity against A549 (human lung cancer)
|
[PMID: 14552770] |
| A549 | ED50 |
6.9 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| A549 | IC50 |
0.069 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 17498951] |
| A549 | IC50 |
0.004 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
|
[PMID: 17673337] |
| A549 | IC50 |
0.067 μM
Compound: CPT, campothecin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 17827007] |
| A549 | IC50 |
3.12 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 18095653] |
| A549 | GI50 |
2.8 μM
Compound: 1, camptothecin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 18180162] |
| A549 | IC50 |
0.01 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells after 4 days by MTT assay
Cytotoxicity against human A549 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| A549 | IC50 |
3.1 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 19256478] |
| A549 | IC50 |
0.058 μM
Compound: CPT
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 19345580] |
| A549 | IC50 |
0.047 μM
Compound: 1, CPT
|
Antitumor activity against human A549/ATCC cells by SRB method
Antitumor activity against human A549/ATCC cells by SRB method
|
[PMID: 19541483] |
| A549 | GI50 |
0.01 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| A549 | IC50 |
0.04 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human A549 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| A549 | IC50 |
5.379 nM
Compound: CPT
|
Cytotoxicity against human A549 cells after 48 hrs by MTT method
Cytotoxicity against human A549 cells after 48 hrs by MTT method
|
[PMID: 20063889] |
| A549 | GI50 |
2.8 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| A549 | IC50 |
0.057 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 20942490] |
| A549 | IC50 |
3.6 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 20961093] |
| A549 | IC50 |
0.03 μM
Compound: Camptothecin
|
Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| A549 | IC50 |
0.069 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 21095131] |
| A549 | IC50 |
0.069 μM
Compound: CPT
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21353568] |
| A549 | GI50 |
0.2 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| A549 | IC50 |
0.072 μg/mL
Compound: CPT
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 21684168] |
| A549 | IC50 |
0.091 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21873069] |
| A549 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 22044245] |
| A549 | IC50 |
0.008 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells after 2 days by MTT assay
Cytotoxicity against human A549 cells after 2 days by MTT assay
|
[PMID: 22325897] |
| A549 | IC50 |
33.8 nM
Compound: 1, CPT
|
Cytotoxicity against human A549 after 72 hrs by SRB assay
Cytotoxicity against human A549 after 72 hrs by SRB assay
|
[PMID: 22647222] |
| A549 | GI50 |
0.17 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| A549 | IC50 |
2.61 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 3 days by MTT assay
Antiproliferative activity against human A549 cells after 3 days by MTT assay
|
[PMID: 23084702] |
| A549 | IC50 |
0.0158 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 23102893] |
| A549 | GI50 |
0.007 μM
Compound: Camptothecin
|
Growth inhibition of human A549 cells after 48 hrs by MTT assay
Growth inhibition of human A549 cells after 48 hrs by MTT assay
|
[PMID: 23357037] |
| A549 | IC50 |
67 nM
Compound: 1, CPT, NSC-100880
|
Cytotoxicity against human A549 cells by WST assay
Cytotoxicity against human A549 cells by WST assay
|
[PMID: 23578545] |
| A549 | IC50 |
37.05 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells after 72 hrs ny MTT assay
Cytotoxicity against human A549 cells after 72 hrs ny MTT assay
|
[PMID: 23974020] |
| A549 | IC50 |
0.65 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 24069881] |
| A549 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Growth inhibition of human A549 cells after 72 hrs by MTT assay
Growth inhibition of human A549 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| A549 | IC50 |
99 nM
Compound: CPT
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| A549 | IC50 |
0.016 μM
Compound: 1, CPT
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 25003995] |
| A549 | IC50 |
1.3 μM
Compound: 3
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25084144] |
| A549 | IC50 |
1 nM
Compound: camptothecin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25237727] |
| A549 | IC50 |
1 x 10-3 μM
Compound: camptothecin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25237727] |
| A549 | IC50 |
26.45 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25599951] |
| A549 | IC50 |
1.6 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26188908] |
| A549 | IC50 |
0.1 μM
Compound: CPT
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| A549 | IC50 |
0.016 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 26994847] |
| A549 | IC50 |
1 nM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 27017547] |
| A549 | IC50 |
1 x 10-3 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 27017547] |
| A549 | IC50 |
0.009 μM
Compound: Camptothecin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
|
[PMID: 27096049] |
| A549 | IC50 |
0.35 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 27156772] |
| A549 | IC50 |
0.12 μM
Compound: Camptothecin
|
Growth inhibition of human A549 cells after 72 hrs by MTT assay
Growth inhibition of human A549 cells after 72 hrs by MTT assay
|
[PMID: 27344492] |
| A549 | IC50 |
0.46 μM
Compound: 1; CPT
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27416553] |
| A549 | IC50 |
5.93 μM
Compound: CPT
|
Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay
|
[PMID: 27721148] |
| A549 | IC50 |
0.006 μM
Compound: 1; CPT
|
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 27871039] |
| A549 | IC50 |
0.24 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28063351] |
| A549 | IC50 |
8.63 nM
Compound: 1; CPT
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 28285912] |
| A549 | IC50 |
0.26 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 28351590] |
| A549 | IC50 |
13.64 μM
Compound: Camptothecin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28462840] |
| A549 | IC50 |
0.7 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 28506750] |
| A549 | IC50 |
<1 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28511910] |
| A549 | IC50 |
8.87 μM
Compound: Camptothecin
|
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382] |
| A549 | IC50 |
5.93 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28923388] |
| A549 | IC50 |
8.63 nM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 28927790] |
| A549 | IC50 |
1 nM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
|
[PMID: 29501943] |
| A549 | IC50 |
1 x 10-3 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
|
[PMID: 29501943] |
| A549 | GI50 |
0.003 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| A549 | IC50 |
5.5 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30025344] |
| A549 | IC50 |
2.21 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| A549 | GI50 |
0.21 μM
Compound: 1
|
Growth inhibition of human A549 cells after 72 hrs by MTT assay
Growth inhibition of human A549 cells after 72 hrs by MTT assay
|
[PMID: 30336023] |
| A549 | IC50 |
1.31 μM
Compound: CPT
|
Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| A549 | IC50 |
0.09 μM
Compound: CPT; 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30509782] |
| A549 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 30543429] |
| A549 | IC50 |
4.43 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| A549 | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells after 48 hrs by CCK8 assay
Cytotoxicity against human A549 cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| A549 | IC50 |
32.11 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 30853330] |
| A549 | IC50 |
50.88 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay
|
[PMID: 30853330] |
| A549 | IC50 |
3.32 μM
Compound: Camptothecin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 30902399] |
| A549 | GI50 |
0.099 μM
Compound: CPT
|
Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay
Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 31176097] |
| A549 | IC50 |
1 nM
Compound: I; CPT
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 31229877] |
| A549 | IC50 |
1 x 10-3 μM
Compound: I; CPT
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 31229877] |
| A549 | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| A549 | IC50 |
2.8 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| A549 | IC50 |
1 μM
Compound: I; CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 32279049] |
| A549 | IC50 |
0.039 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 32292547] |
| A549 | IC50 |
1.56 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| A549 | IC50 |
32.1 μM
Compound: Camptophecin
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 33421712] |
| A549 | IC50 |
1 nM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
|
[PMID: 33962152] |
| A549 | IC50 |
1 x 10-3 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
|
[PMID: 33962152] |
| A549 | GI50 |
0.31 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 34008967] |
| A549 | IC50 |
0.17 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
|
[PMID: 34052678] |
| A549 | IC50 |
0.1 μM
Compound: 1; CPT
|
Antiproliferative activity against human A549 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| A549 | IC50 |
8.9 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34852457] |
| A549 | IC50 |
1 nM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
|
[PMID: 34952177] |
| A549 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| A549 | IC50 |
0.074 μM
Compound: CPT
|
In-vitro antitumor activity against human A549 cells incubated for 72 hrs by CCK8 assay
In-vitro antitumor activity against human A549 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 35550978] |
| A549 | IC50 |
0.37 μM
Compound: CPT
|
Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| A549 | IC50 |
0.47 μM
Compound: CPT
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 35635947] |
| A549 | IC50 |
5.5 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| A549 | IC50 |
7.8 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| A549 | IC50 |
0.39 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38169246] |
| A549 | IC50 |
106.3 μM
Compound: CPT
|
Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| A549 | EC50 |
4.17 nM
Compound: 1; CPT
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 38421819] |
| A549 | GI50 |
5.69 ng/mL
Compound: 1; CPT
|
Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay
Growth inhibition of human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| A549 | IC50 |
0.32 ng/mL
Compound: 1; CPT
|
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| A549 | IC50 |
0.32 nM
Compound: 1; CPT
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38421819] |
| A549 | IC50 |
0.39 μM
Compound: Camptothecin
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 38665827] |
| A549 | IC50 |
0.021 μM
Compound: CPT
|
Cytotoxicity against human A549 cells measured after 72 hrs
Cytotoxicity against human A549 cells measured after 72 hrs
|
[PMID: 38716896] |
| ADR5000 cell line | IC50 |
0.3 μM
Compound: CPT
|
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281] |
| ADR5000 cell line | IC50 |
0.011 μM
Compound: Camptothecin
|
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
|
[PMID: 28233677] |
| AGS | GI50 |
23.76 μM
Compound: 1, camptothecin
|
Antiproliferative activity against human AGS cells after 48 hrs by MTT assay
Antiproliferative activity against human AGS cells after 48 hrs by MTT assay
|
[PMID: 18180162] |
| AGS | GI50 |
0.01 μM
Compound: 1, CPT
|
Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| AGS | IC50 |
0.02 μM
Compound: 1, CPT
|
Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human AGS cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| AGS | IC50 |
23.76 μM
Compound: CPT
|
Antiproliferative activity against human AGS cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human AGS cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| B16-F10 | IC50 |
2.78 μM
Compound: Camptothecin
|
Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay
|
[PMID: 24685545] |
| Bel-7402 | IC50 |
0.007 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against Bel7402 (human liver cancer)
In vitro cytotoxicity against Bel7402 (human liver cancer)
|
[PMID: 14552770] |
| Bel-7402 | IC50 |
2.72 μg/mL
Compound: 1 Camptothecin
|
In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay
In vitro cytotoxicity against Bel7402 cell line (human liver cancer) using MTT assay
|
[PMID: 15225719] |
| Bel-7402 | IC50 |
12.5 μM
Compound: camptothecin
|
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 18095653] |
| Bel-7402 | IC50 |
0.17 μM
Compound: 1, CPT
|
Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay
Cytotoxicity against human BEL-7402 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| Bel-7402 | IC50 |
12.5 μM
Compound: camptothecin
|
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 19256478] |
| Bel-7402 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 22044245] |
| Bel-7402 | IC50 |
6.3 μM
Compound: camptothecin
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 25237727] |
| Bel-7402 | IC50 |
0.014 μM
Compound: 1; CPT
|
Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 27871039] |
| BEL-7404 tumor cell line | IC50 |
0.14 μM
Compound: CPT
|
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| BEL-7404 tumor cell line | IC50 |
0.4 μM
Compound: CPT
|
Antiproliferative activity against human Bel7404 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human Bel7404 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| BGC-823 | IC50 |
9.67 μM
Compound: camptothecin
|
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 18095653] |
| BGC-823 | IC50 |
9.7 μM
Compound: camptothecin
|
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 19256478] |
| BGC-823 | IC50 |
0.21 μM
Compound: camptothecin
|
Cytotoxicity against human BGC823 cells
Cytotoxicity against human BGC823 cells
|
[PMID: 19916529] |
| BGC-823 | IC50 |
0.04 μM
Compound: camptothecin
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 25237727] |
| BGC-823 | IC50 |
1.27 μM
Compound: 1; CPT
|
Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay
|
[PMID: 27416553] |
| BGC-823 | IC50 |
0.057 μM
Compound: 1; CPT
|
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 27871039] |
| BJ | IC50 |
>40 μM
Compound: Camp
|
Cytotoxicity against human BJ cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human BJ cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| BT-20 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human BT20 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human BT20 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| BT-20 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human BT20 cells after 3 days by SRB assay
Cytotoxicity against human BT20 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| BT-20 | IC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human BT20 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human BT20 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 27017547] |
| BT-474 | IC50 |
12.75 μM
Compound: CPT
|
Cytotoxicity against human BT474 cells after 3 days by SRB assay
Cytotoxicity against human BT474 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| BT-474 | IC50 |
7 μM
Compound: Camptothecin
|
Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
|
[PMID: 26988802] |
| BT-483 | GI50 |
1.03 μM
Compound: CPT
|
Cytotoxicity against human BT-483 cells after 48 hrs by MTT assay
Cytotoxicity against human BT-483 cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| BXPC-3 | IC50 |
0.24 μM
Compound: 1, CPT
|
Cytotoxicity against human BXPC3 cells after 4 days by MTT assay
Cytotoxicity against human BXPC3 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| BXPC-3 | IC50 |
62.5 nM
Compound: CPT
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth
|
[PMID: 37806498] |
| C6 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| CA46 | IC50 |
0.52 μM
Compound: CPT
|
Cytotoxicity against human CA46 cells after 48 hrs by MTT assay
Cytotoxicity against human CA46 cells after 48 hrs by MTT assay
|
[PMID: 26188908] |
| Caco-2 | IC50 |
9.55 μM
Compound: Camptothecin
|
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 21843907] |
| Caco-2 | IC50 |
0.131 μM
Compound: CPT, Camptothecin
|
Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay
|
[PMID: 24980118] |
| CAKI-2 | IC50 |
3.96 μM
Compound: Camptothecin
|
In vitro antiproliferative activity of compound against Caki-2 (human renal caner ) cell line was determined by SRB assay
In vitro antiproliferative activity of compound against Caki-2 (human renal caner ) cell line was determined by SRB assay
|
[PMID: 12639541] |
| CAMA-1 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human CAMA1 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human CAMA1 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| CAMA-1 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human CAMA1 cells after 3 days by SRB assay
Cytotoxicity against human CAMA1 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| CAMA-1 | IC50 |
0.07 μM
Compound: Camptothecin
|
Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition
Antiproliferative activity against human CAMA-1 cells assessed as cell growth inhibition
|
[PMID: 38107170] |
| CAPAN-1 | IC50 |
0.21 μM
Compound: CPT
|
Cytotoxicity against human Capan1 cells after 72 hrs by XTT assay
Cytotoxicity against human Capan1 cells after 72 hrs by XTT assay
|
[PMID: 30017114] |
| carcinoma cell line | IC50 |
0.33 μM
Compound: CPT (Camptothecin)
|
Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)
Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460)
|
[PMID: 11563925] |
| Ca-Ski | IC50 |
1.8 μM
Compound: Camptothecin
|
Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay
Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay
|
[PMID: 29407986] |
| Ca-Ski | IC50 |
>300 μM
Compound: CPT
|
Antiproliferative activity against human Ca-Ski cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Ca-Ski cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| CCD 19Lu | IC50 |
2 μg/mL
Compound: Camptothecin (CPT)
|
Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
|
10.1016/S0960-894X(97)00071-1 |
| CCRF-CEM | IC50 |
5.3 μM
Compound: Camptothecin
|
Cytotoxicity in human leukemic CCRF-CEM cells.
Cytotoxicity in human leukemic CCRF-CEM cells.
|
[PMID: 14667232] |
| CCRF-CEM | IC50 |
0.84 nM
Compound: CPT
|
Inhibitory concentration against CEM cell growth after incubation in liquid medium for 72 h
Inhibitory concentration against CEM cell growth after incubation in liquid medium for 72 h
|
[PMID: 15916431] |
| CCRF-CEM | IC50 |
0.003 μM
Compound: CPT
|
Antiproliferative activity against human CCRF-CEM cells by MTT assay
Antiproliferative activity against human CCRF-CEM cells by MTT assay
|
[PMID: 17254669] |
| CCRF-CEM | GI50 |
0.002 μM
Compound: camptothecin
|
Growth inhibition of human CEM cells by Alamar blue assay
Growth inhibition of human CEM cells by Alamar blue assay
|
[PMID: 17418582] |
| CCRF-CEM | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against p38-proficient human CCRF-CEM cells after 3 days by MTT assay
Cytotoxicity against p38-proficient human CCRF-CEM cells after 3 days by MTT assay
|
[PMID: 19203291] |
| CCRF-CEM | GI50 |
0.023 nM
Compound: camptothecin
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858] |
| CCRF-CEM | GI50 |
43.21 nM
Compound: camptothecin
|
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858] |
| CCRF-CEM | CC50 |
0.003 μM
Compound: Camptothecin
|
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| CCRF-CEM | IC50 |
0.005 μM
Compound: CPT
|
Cytotoxicity against human CEM cells
Cytotoxicity against human CEM cells
|
[PMID: 22305342] |
| CCRF-CEM | CC50 |
0.003 μM
Compound: Camptothecin
|
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| CCRF-CEM | GI50 |
2 nM
Compound: Camptothecin
|
Growth inhibition of human CEM cells
Growth inhibition of human CEM cells
|
[PMID: 23750455] |
| CCRF-CEM | IC50 |
0.08 μM
Compound: CPT
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281] |
| CCRF-CEM | IC50 |
0.003 μM
Compound: Camptothecin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
|
[PMID: 28233677] |
| CCRF-CEM | GI50 |
0.002 μM
Compound: CPT
|
Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| CCRF-CEM | GI50 |
0.007 μM
Compound: 1
|
Growth inhibition of human CCRF-CEM cells after 72 hrs by MTT assay
Growth inhibition of human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 30336023] |
| CCRF-CEM | IC50 |
0.002 μM
Compound: CPT
|
Cytotoxicity against human CCRF-CEM cells by MTT assay
Cytotoxicity against human CCRF-CEM cells by MTT assay
|
[PMID: 30543429] |
| CCRF-CEM | IC50 |
0.005 μg/mL
Compound: Camptothecin (CPT)
|
Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
|
10.1016/S0960-894X(97)00071-1 |
| CCRF-SB | IC50 |
0.003 μM
Compound: CPT
|
Antiproliferative activity against human CCRF-SB cells by MTT assay
Antiproliferative activity against human CCRF-SB cells by MTT assay
|
[PMID: 17254669] |
| CCRF-SB | CC50 |
0.004 μM
Compound: Camptothecin
|
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| CCRF-SB | CC50 |
0.004 μM
Compound: Camptothecin
|
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| CEM/C2 | IC50 |
5385 nM
Compound: CPT
|
Inhibitory concentration against CEM/C2 cell growth after incubation in liquid medium for 72 h
Inhibitory concentration against CEM/C2 cell growth after incubation in liquid medium for 72 h
|
[PMID: 15916431] |
| CEM/C2 | GI50 |
>1 μM
Compound: camptothecin
|
Growth inhibition of topoisomerase 1 mutated CEM/C2 cells by Alamar blue assay
Growth inhibition of topoisomerase 1 mutated CEM/C2 cells by Alamar blue assay
|
[PMID: 17418582] |
| CEM/C2 | GI50 |
1000 nM
Compound: Camptothecin
|
Growth inhibition of multidrug-resistant human CEM/C2 cells
Growth inhibition of multidrug-resistant human CEM/C2 cells
|
[PMID: 23750455] |
| CNE | IC50 |
0.34 μM
Compound: CPT
|
Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay
Antiproliferative activity against human CNE1 cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| CNE-2 | IC50 |
0.1 μM
Compound: Camptothecin
|
Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30025344] |
| CNE-2 | IC50 |
0.98 μM
Compound: CPT
|
Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay
Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| Col2 | ED50 |
57 nM
Compound: camptothecin
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 15043407] |
| Col2 | IC50 |
0.045 μM
Compound: camptothecin
|
Cytotoxicity against human Col2 cells by SRB assay
Cytotoxicity against human Col2 cells by SRB assay
|
[PMID: 17498951] |
| Col2 | IC50 |
0.045 μM
Compound: 1, CPT
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 21095131] |
| Col2 | IC50 |
0.045 μM
Compound: CPT
|
Cytotoxicity against human Col2 cells by MTT assay
Cytotoxicity against human Col2 cells by MTT assay
|
[PMID: 21353568] |
| COLO 201 | IC50 |
27 μM
Compound: Camptothecin
|
Cytotoxicity against human COLO201 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay
Cytotoxicity against human COLO201 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay
|
[PMID: 39018435] |
| COLO 205 | IC50 |
5.4 nM
Compound: 1
|
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (COLO 205)
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human colorectal cells (COLO 205)
|
[PMID: 10479293] |
| COLO 205 | IC50 |
0.05 μM
Compound: Camptothecin
|
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
|
[PMID: 24041234] |
| CRL-7065 cell line | IC50 |
0.5 μM
Compound: CPT
|
Antiproliferative activity against human CRL7065 cells by MTT assay
Antiproliferative activity against human CRL7065 cells by MTT assay
|
[PMID: 17254669] |
| CRL-7065 cell line | CC50 |
0.3 μM
Compound: Camptothecin
|
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| CRL-7065 cell line | CC50 |
0.3 μM
Compound: Camptothecin
|
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| CT26 | IC50 |
34 nM
Compound: camptothecin
|
Antiproliferative activity against mouse CT26 cell line
Antiproliferative activity against mouse CT26 cell line
|
[PMID: 16686539] |
| CT26.WT | IC50 |
0.43 μM
Compound: CPT
|
Antiproliferative activity against mouse CT26.WT cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against mouse CT26.WT cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 35868003] |
| Daudi | IC50 |
118.9 μM
Compound: CPT
|
Antiproliferative activity against human Daudi cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Daudi cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| DC3F | IC50 |
6 nM
Compound: CPT
|
Tested in vitro for growth inhibitory activity against DC-3F (hamster lung) cells
Tested in vitro for growth inhibitory activity against DC-3F (hamster lung) cells
|
10.1016/S0960-894X(97)10181-0 |
| Detroit 551 | GI50 |
0.99 μM
Compound: CPT
|
Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay
Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay
|
[PMID: 20591678] |
| Detroit 551 | GI50 |
0.99 μM
Compound: CPT
|
Cytotoxicity against human Detroit 551 cells after 48 hrs by MTT assay
Cytotoxicity against human Detroit 551 cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| Detroit 551 | IC50 |
0.99 μM
Compound: CPT
|
Antiproliferative activity against human Detroit 551 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human Detroit 551 cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| DLD-1 | IC50 |
14000 μM
Compound: C (20)(S)-1
|
In vitro cytotoxicity against human tumor cell line DLD-1
In vitro cytotoxicity against human tumor cell line DLD-1
|
[PMID: 10576688] |
| DLD-1 | IC50 |
0.21 μM
Compound: CPT ((S)-Camptothecin)
|
Cytotoxicity against DLD-1 human tumor cell lines
Cytotoxicity against DLD-1 human tumor cell lines
|
10.1016/0960-894X(96)00131-X |
| DLD-1 | IC50 |
0.21 μM
Compound: 13 ((S)-CPT, Camptothecin)
|
In vitro cytotoxicity against DLD-1 human tumor cell lines.
In vitro cytotoxicity against DLD-1 human tumor cell lines.
|
10.1016/0960-894X(96)00132-1 |
| DU-145 | GI50 |
0.01 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line
Antiproliferative activity was determined for 50% growth inhibition against human Prostate DU-145 cell line
|
[PMID: 11020283] |
| DU-145 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibitory activity against human prostate DU-145 cell line
Growth inhibitory activity against human prostate DU-145 cell line
|
[PMID: 15509164] |
| DU-145 | GI50 |
0.01 μM
Compound: Camptothecin
|
Concentration required to inhibit the growth of human ProstateDU-145 cells
Concentration required to inhibit the growth of human ProstateDU-145 cells
|
[PMID: 16033260] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human DU145 cell line
Antiproliferative activity against human DU145 cell line
|
[PMID: 16442283] |
| DU-145 | GI50 |
0.01 μM
Compound: 2
|
Antiproliferative activity against human DU145 cell line
Antiproliferative activity against human DU145 cell line
|
[PMID: 16913702] |
| DU-145 | IC50 |
0.01 μM
Compound: CPT
|
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
|
[PMID: 17254669] |
| DU-145 | ED50 |
10.9 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human DU145 cells by sulforhodamine B assay
Cytotoxicity against human DU145 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 17402722] |
| DU-145 | GI50 |
0.01 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 17676830] |
| DU-145 | GI50 |
0.01 μM
Compound: 2
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 17696418] |
| DU-145 | IC50 |
3.2 μM
Compound: camptothecin
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 18178085] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells
Antiproliferative activity against human DU145 cells
|
[PMID: 18630891] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 19783447] |
| DU-145 | IC50 |
1 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 19836231] |
| DU-145 | IC50 |
0.66 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
|
[PMID: 19939682] |
| DU-145 | IC50 |
1.46 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 3 days
Cytotoxicity against human DU145 cells after 3 days
|
[PMID: 19954977] |
| DU-145 | IC50 |
3.57 μM
Compound: camptothecin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 20093033] |
| DU-145 | GI50 |
0.01 μM
Compound: 1, CPT
|
Antiproliferative activity against human DU145 cells
Antiproliferative activity against human DU145 cells
|
[PMID: 20155916] |
| DU-145 | IC50 |
0.94 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum
Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum
|
[PMID: 20188578] |
| DU-145 | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
|
[PMID: 20392646] |
| DU-145 | IC50 |
3.2 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 4 days by MTT assay
Cytotoxicity against human DU145 cells after 4 days by MTT assay
|
[PMID: 20619511] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 20630766] |
| DU-145 | IC50 |
0.02 μM
Compound: Camptothecin
|
Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| DU-145 | IC50 |
0.61 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 21115246] |
| DU-145 | IC50 |
0.31 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 21419530] |
| DU-145 | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 21601964] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells by SRB assay
Antiproliferative activity against human DU145 cells by SRB assay
|
[PMID: 21710981] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| DU-145 | CC50 |
0.015 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| DU-145 | IC50 |
0.015 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 96 hrs
Cytotoxicity against human DU145 cells after 96 hrs
|
[PMID: 22276775] |
| DU-145 | IC50 |
2.37 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 22318164] |
| DU-145 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| DU-145 | IC50 |
1.06 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656] |
| DU-145 | IC50 |
9.29 μM
Compound: CPT
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 22819942] |
| DU-145 | CC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| DU-145 | IC50 |
0.0287 μM
Compound: 1, CPT
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 23102893] |
| DU-145 | IC50 |
0.39 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
|
[PMID: 24013413] |
| DU-145 | IC50 |
0.8 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 24 to 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 to 72 hrs by MTT assay
|
[PMID: 24303808] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 24502276] |
| DU-145 | GI50 |
18.2 nM
Compound: 1
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 24502276] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| DU-145 | IC50 |
4.01 μM
Compound: CPT
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 24904965] |
| DU-145 | IC50 |
0.029 μM
Compound: 1, CPT
|
Cytotoxicity against human DU145 cells after 72 hrs by SRB assay
Cytotoxicity against human DU145 cells after 72 hrs by SRB assay
|
[PMID: 25003995] |
| DU-145 | IC50 |
0.95 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
|
[PMID: 25062006] |
| DU-145 | IC50 |
0.11 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
|
[PMID: 25481396] |
| DU-145 | IC50 |
0.1 μM
Compound: CPT
|
Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
|
[PMID: 25799376] |
| DU-145 | IC50 |
0.02 μM
Compound: camptothecin
|
Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
|
[PMID: 25936262] |
| DU-145 | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
|
[PMID: 26022080] |
| DU-145 | IC50 |
0.11 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
|
[PMID: 26361737] |
| DU-145 | IC50 |
0.02 μM
Compound: Camptothecin
|
Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
|
[PMID: 26945111] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells after 48 hrs
Antiproliferative activity against human DU145 cells after 48 hrs
|
[PMID: 27070999] |
| DU-145 | IC50 |
0.11 μM
Compound: Camptothecin
|
Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| DU-145 | IC50 |
0.38 μM
Compound: Camptothecin
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
|
[PMID: 27654394] |
| DU-145 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells assessed as growth inhibition
Antiproliferative activity against human DU145 cells assessed as growth inhibition
|
[PMID: 28657311] |
| DU-145 | GI50 |
0.019 μM
Compound: CPT
|
Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| DU-145 | GI50 |
0.021 μM
Compound: 1
|
Growth inhibition of human DU145 cells after 72 hrs by MTT assay
Growth inhibition of human DU145 cells after 72 hrs by MTT assay
|
[PMID: 30336023] |
| DU-145 | IC50 |
0.016 μM
Compound: CPT
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 30543429] |
| DU-145 | GI50 |
0.21 μM
Compound: CPT
|
Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay
Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay
|
[PMID: 31176097] |
| DU-145 | IC50 |
0.05 μM
Compound: Camptothecin
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
|
[PMID: 31398033] |
| DU-145 | IC50 |
1.99 μM
Compound: Camptothecin
|
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
|
[PMID: 32526552] |
| DU-145 | IC50 |
0.07 μM
Compound: 45
|
Anti-proliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Anti-proliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 33143937] |
| DU-145 | GI50 |
0.21 μM
Compound: CPT
|
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 34008967] |
| DU-145 | IC50 |
0.21 μM
Compound: CPT
|
Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34678573] |
| DU-145 | IC50 |
0.61 μM
Compound: Camptothecin
|
Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis
Antiproliferative activity against human DU-145 cells incubated for 72 hrs by microplate reader analysis
|
[PMID: 37418826] |
| DU-145 | IC50 |
33.45 nM
Compound: CPT
|
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth
|
[PMID: 37806498] |
| DU-145 | IC50 |
0.042 μM
Compound: CPT
|
Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| ECa-109 cell line | IC50 |
9.52 μM
Compound: CPT
|
Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
|
[PMID: 27667553] |
| Erythrocyte | EC50 |
429.9 μg/mL
Compound: Camptothecin
|
Hemolytic activity in Homo sapiens (human) Erythrocyte after 30 min
Hemolytic activity in Homo sapiens (human) Erythrocyte after 30 min
|
10.1007/s00044-010-9381-7 |
| Fibroblast | IC50 |
459.3 nM
Compound: camptothecin
|
Cytotoxicity against human Fibroblasts by SRB assay
Cytotoxicity against human Fibroblasts by SRB assay
|
[PMID: 21410162] |
| GLC4 cell line | IC50 |
10 nM
Compound: Cpt
|
Cytotoxicity against human GLC4 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human GLC4 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 22749423] |
| H22 | IC50 |
0.54 μM
Compound: 1; CPT
|
Antiproliferative activity against mouse H22 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse H22 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| H69AR | IC50 |
>300 nM
Compound: 1a
|
Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay
Cytotoxicity against human H69AR cells overexpressing MDR1 after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| HBL-100 | GI50 |
0.23 μM
Compound: CPT
|
Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| HBL-100 | GI50 |
0.23 μM
Compound: Camptothecin
|
Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay
Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay
|
[PMID: 23831507] |
| HBL-100 | GI50 |
0.2 μM
Compound: Camptothecin
|
Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
|
[PMID: 37531922] |
| HCC70 | IC50 |
0.044 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
|
[PMID: 31398033] |
| HCCLM9 | IC50 |
>150 μM
Compound: CPT
|
Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HCT-116 | GI50 |
0.03 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line
Antiproliferative activity was determined for 50% growth inhibition against human colon HCT116 cell line
|
[PMID: 11020283] |
| HCT-116 | IC50 |
0.009 μM
Compound: camptothecin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS method
Cytotoxicity against human HCT116 cells after 72 hrs by MTS method
|
[PMID: 11858737] |
| HCT-116 | GI50 |
0.03 μM
Compound: 2
|
Growth inhibitory activity against human colon HCT116 cell line
Growth inhibitory activity against human colon HCT116 cell line
|
[PMID: 15509164] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cell line
Antiproliferative activity against human HCT116 cell line
|
[PMID: 16442283] |
| HCT-116 | GI50 |
0.03 μM
Compound: 2
|
Antiproliferative activity against human HCT116 cell line
Antiproliferative activity against human HCT116 cell line
|
[PMID: 16913702] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 17402722] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 17676830] |
| HCT-116 | GI50 |
0.03 μM
Compound: 2
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 17696418] |
| HCT-116 | IC50 |
1 μM
Compound: camptothecin
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 18178085] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 18630891] |
| HCT-116 | IC50 |
2 nM
Compound: camptothecin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| HCT-116 | IC50 |
0.13 μM
Compound: CPT
|
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 19783447] |
| HCT-116 | IC50 |
2.77 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT116 cells after 3 days
Cytotoxicity against human HCT116 cells after 3 days
|
[PMID: 19954977] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1, CPT
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 20155916] |
| HCT-116 | IC50 |
2.3 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
|
[PMID: 20619511] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 20630766] |
| HCT-116 | IC50 |
3.97 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT116 cells after 2 days
Cytotoxicity against human HCT116 cells after 2 days
|
[PMID: 21419530] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells by SRB assay
Antiproliferative activity against human HCT116 cells by SRB assay
|
[PMID: 21710981] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| HCT-116 | GI50 |
0.03 μM
Compound: 2
|
Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| HCT-116 | IC50 |
<0.1 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 22409771] |
| HCT-116 | IC50 |
22.9 nM
Compound: 1, CPT
|
Cytotoxicity against human HCT116 after 72 hrs by SRB assay
Cytotoxicity against human HCT116 after 72 hrs by SRB assay
|
[PMID: 22647222] |
| HCT-116 | GI50 |
0.083 μM
Compound: 1, CPT
|
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| HCT-116 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| HCT-116 | IC50 |
0.11 μM
Compound: CPT
|
Antiproliferative activity against human HCT116 cells after 3 days by MTT assay
Antiproliferative activity against human HCT116 cells after 3 days by MTT assay
|
[PMID: 23084702] |
| HCT-116 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells after 3 days by SRB assay
Cytotoxicity against human HCT116 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| HCT-116 | IC50 |
0.016 μM
Compound: camptothecin
|
Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay
Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay
|
[PMID: 24033077] |
| HCT-116 | IC50 |
0.07 μM
Compound: 1, CPT
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 24069881] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 24502276] |
| HCT-116 | GI50 |
17.38 nM
Compound: 1
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 24502276] |
| HCT-116 | GI50 |
35.48 nM
Compound: 1
|
Cytotoxicity against human HCT116 cells transfected with Top1-siRNA after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells transfected with Top1-siRNA after 72 hrs by MTT assay
|
[PMID: 24502276] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Growth inhibition of human HCT116 cells after 48 hrs by SRB assay
Growth inhibition of human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| HCT-116 | IC50 |
0.00015 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 25247770] |
| HCT-116 | IC50 |
0.09 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| HCT-116 | IC50 |
≤0.1 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells after 48 hrs
Antiproliferative activity against human HCT116 cells after 48 hrs
|
[PMID: 27070999] |
| HCT-116 | IC50 |
0.003 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
|
[PMID: 27096049] |
| HCT-116 | IC50 |
0.159 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27318980] |
| HCT-116 | IC50 |
6.7 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells measured after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells measured after 72 hrs by MTT assay
|
[PMID: 27721148] |
| HCT-116 | IC50 |
0.12 μM
Compound: CPT
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 28351590] |
| HCT-116 | IC50 |
0.0115 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 28454671] |
| HCT-116 | IC50 |
0.159 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT116 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells measured after 48 hrs by MTT assay
|
[PMID: 28477443] |
| HCT-116 | GI50 |
0.03 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells assessed as growth inhibition
Antiproliferative activity against human HCT116 cells assessed as growth inhibition
|
[PMID: 28657311] |
| HCT-116 | IC50 |
1.88 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28923388] |
| HCT-116 | GI50 |
0.05 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| HCT-116 | GI50 |
0.195 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT-116 p53-/- cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human HCT-116 p53-/- cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| HCT-116 | GI50 |
0.009 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| HCT-116 | GI50 |
0.075 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells expressing TOP1 siRNA assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells expressing TOP1 siRNA assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| HCT-116 | GI50 |
0.009 μM
Compound: 1
|
Growth inhibition of human HCT116 cells after 72 hrs by MTT assay
Growth inhibition of human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 30336023] |
| HCT-116 | GI50 |
0.075 μM
Compound: 1
|
Growth inhibition of human HCT116 cells expressing TOP1 siRNA after 72 hrs by MTT assay
Growth inhibition of human HCT116 cells expressing TOP1 siRNA after 72 hrs by MTT assay
|
[PMID: 30336023] |
| HCT-116 | IC50 |
1.88 μM
Compound: CPT
|
Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| HCT-116 | IC50 |
0.013 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 30543429] |
| HCT-116 | GI50 |
0.009 μM
Compound: CPT
|
Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay
Growth inhibition of human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 31176097] |
| HCT-116 | GI50 |
0.075 μM
Compound: CPT
|
Growth inhibition of human HCT116 cells expressing siTOP1 incubated for 72 hrs by MTT assay
Growth inhibition of human HCT116 cells expressing siTOP1 incubated for 72 hrs by MTT assay
|
[PMID: 31176097] |
| HCT-116 | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HCT-116 | IC50 |
0.02 μM
Compound: CPT
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| HCT-116 | IC50 |
0.009 μM
Compound: CPT
|
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 32292547] |
| HCT-116 | IC50 |
0.4 μM
Compound: CPT
|
Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 32668379] |
| HCT-116 | IC50 |
0.05 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| HCT-116 | IC50 |
8.5 nM
Compound: Camptothecin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay
|
[PMID: 32952994] |
| HCT-116 | IC50 |
0.25 μM
Compound: CPT
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33158579] |
| HCT-116 | GI50 |
0.05 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 34008967] |
| HCT-116 | IC50 |
0.017 μM
Compound: CPT
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
|
[PMID: 34052678] |
| HCT-116 | IC50 |
0.09 μM
Compound: 1; CPT
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| HCT-116 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HCT-116 | IC50 |
0.04 μM
Compound: CPT
|
In-vitro antitumor activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay
In-vitro antitumor activity against human HCT-116 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 35550978] |
| HCT-116 | IC50 |
2.01 nM
Compound: Camptothecin
|
Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell viability incubated for 24 hrs by MTT assay
|
[PMID: 35567964] |
| HCT-116 | IC50 |
0.6 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| HCT-116 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells
Cytotoxicity against human HCT-116 cells
|
[PMID: 36924947] |
| HCT-116 | IC50 |
0.21 μM
Compound: CPT
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HCT-116 | IC50 |
0.051 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| HCT-116 | EC50 |
3.15 nM
Compound: 1; CPT
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 38421819] |
| HCT-116 | GI50 |
3.86 ng/mL
Compound: 1; CPT
|
Growth inhibition of human HCT-116 cells incubated for 72 hrs by MTT assay
Growth inhibition of human HCT-116 cells incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| HCT-116 | IC50 |
2.01 ng/mL
Compound: 1; CPT
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| HCT-116 | IC50 |
2.01 nM
Compound: 1; CPT
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38421819] |
| HCT-116 | IC50 |
0.011 μM
Compound: CPT
|
Cytotoxicity against human HCT-116 cells measured after 72 hrs
Cytotoxicity against human HCT-116 cells measured after 72 hrs
|
[PMID: 38716896] |
| HCT-116 | IC50 |
4.75 μM
Compound: Camptothecin
|
Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells
Inhibition of DNA topoisomerase 1 in Homo sapiens (human) HCT116 cells
|
10.1007/s00044-009-9233-5 |
| HCT-15 | IC50 |
18 nM
Compound: camptothecin
|
Antiproliferative activity against human HCT15 cell line
Antiproliferative activity against human HCT15 cell line
|
[PMID: 16686539] |
| HCT-15 | IC50 |
0.083 μM
Compound: camptothecin
|
Cytotoxicity against human HCT15 cells after 48 hrs
Cytotoxicity against human HCT15 cells after 48 hrs
|
[PMID: 17673337] |
| HCT-15 | IC50 |
0.08 μM
Compound: CPT, campothecin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 17827007] |
| HCT-15 | IC50 |
3 nM
Compound: camptothecin
|
Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| HCT-15 | IC50 |
0.76 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
|
[PMID: 19939682] |
| HCT-15 | IC50 |
0.64 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum
Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum
|
[PMID: 20188578] |
| HCT-15 | IC50 |
0.5 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
|
[PMID: 20392646] |
| HCT-15 | IC50 |
0.067 μM
Compound: Camptothecin
|
Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| HCT-15 | IC50 |
0.8 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells by MTT assay
Cytotoxicity against human HCT15 cells by MTT assay
|
[PMID: 21115246] |
| HCT-15 | IC50 |
0.5 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 21601964] |
| HCT-15 | IC50 |
0.096 μg/mL
Compound: CPT
|
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
|
[PMID: 21684168] |
| HCT-15 | IC50 |
0.166 μM
Compound: CPT
|
Cytotoxicity against human HCT15 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT15 cells after 48 hrs by MTT assay
|
[PMID: 21873069] |
| HCT-15 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 22318164] |
| HCT-15 | IC50 |
1.38 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656] |
| HCT-15 | IC50 |
9.92 μM
Compound: CPT
|
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
|
[PMID: 22819942] |
| HCT-15 | IC50 |
0.42 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
|
[PMID: 24013413] |
| HCT-15 | IC50 |
10.07 μM
Compound: CPT
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 24904965] |
| HCT-15 | IC50 |
1.98 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
|
[PMID: 25062006] |
| HCT-15 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
|
[PMID: 25481396] |
| HCT-15 | IC50 |
2.82 μM
Compound: camptothecin
|
Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
|
[PMID: 25936262] |
| HCT-15 | IC50 |
0.52 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
|
[PMID: 26022080] |
| HCT-15 | IC50 |
6.08 μM
Compound: CPT
|
Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
|
[PMID: 26334499] |
| HCT-15 | IC50 |
0.3 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
|
[PMID: 26361737] |
| HCT-15 | IC50 |
1.29 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
|
[PMID: 26927425] |
| HCT-15 | IC50 |
2.82 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
|
[PMID: 26945111] |
| HCT-15 | IC50 |
7.1 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
|
[PMID: 26988802] |
| HCT-15 | IC50 |
0.0014 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
|
[PMID: 27484510] |
| HCT-15 | IC50 |
0.31 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| HCT-15 | IC50 |
0.35 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
|
[PMID: 27654394] |
| HCT-15 | IC50 |
0.6 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
|
[PMID: 28068603] |
| HCT-15 | IC50 |
0.26 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
|
[PMID: 28384547] |
| HCT-15 | IC50 |
0.76 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
|
[PMID: 28633898] |
| HCT-15 | IC50 |
0.05 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 29402741] |
| HCT-15 | IC50 |
0.02 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
|
[PMID: 29510948] |
| HCT-15 | IC50 |
0.05 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
|
[PMID: 30262132] |
| HCT-15 | IC50 |
0.049 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
|
[PMID: 31398033] |
| HCT-15 | IC50 |
1.59 μM
Compound: Camptothecin
|
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
|
[PMID: 32526552] |
| HCT-15 | IC50 |
0.08 μM
Compound: CPT
|
Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34678573] |
| HCT-8 | IC50 |
0.007 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against HCT-8 (human colon cancer)
In vitro cytotoxicity against HCT-8 (human colon cancer)
|
[PMID: 14552770] |
| HCT-8 | IC50 |
<0.005 μg/mL
Compound: 1 Camptothecin
|
In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay
In vitro cytotoxicity against HCT-8 cell line (human colon cancer) using MTT assay
|
[PMID: 15225719] |
| HCT-8 | IC50 |
3.15 μM
Compound: camptothecin
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 18095653] |
| HCT-8 | IC50 |
3.2 μM
Compound: camptothecin
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 19256478] |
| HCT-8 | IC50 |
<0.013 μM
Compound: CPT
|
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
|
[PMID: 20392545] |
| HCT-8 | IC50 |
0.26 μM
Compound: Camptothecin
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 22044245] |
| HCT-8 | IC50 |
3.6 μM
Compound: camptothecin
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 25237727] |
| HCT-8 | IC50 |
0.024 μM
Compound: 1; CPT
|
Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay
Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 27871039] |
| HEC-1B cell line | IC50 |
8.64 μM
Compound: Camptothecin
|
In vitro antiproliferative activity of compound against HEC-1-B (human endometrical caner ) cell line was determined by SRB assay
In vitro antiproliferative activity of compound against HEC-1-B (human endometrical caner ) cell line was determined by SRB assay
|
[PMID: 12639541] |
| HEK293 | IC50 |
1.01 μM
Compound: Camptothecin
|
Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656] |
| HEK293 | IC50 |
7.94 μM
Compound: CPT
|
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
|
[PMID: 22819942] |
| HEK293 | IC50 |
0.78 μM
Compound: Camptothecin
|
Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
|
[PMID: 24013413] |
| HEK293 | IC50 |
0.28 μM
Compound: Camptothecin
|
Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
|
[PMID: 25062006] |
| HEK293 | IC50 |
0.83 μM
Compound: Camptothecin
|
Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| HEK293 | IC50 |
0.89 μM
Compound: CPT
|
Cytotoxicity against human HEK293 cells measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells measured after 72 hrs by MTT assay
|
[PMID: 27721148] |
| HEK293 | IC50 |
0.01 μM
Compound: Camptothecin
|
Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells measured after 48 hrs by MTT assay
|
[PMID: 28027871] |
| HEK293 | IC50 |
54.69 μM
Compound: Camptothecin
|
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382] |
| HEK293 | IC50 |
5.6 x 10-4 μM
Compound: CPT
|
Antiproliferative activity against human HEK293 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HEK293 cells after 48 hrs by CCK-8 assay
|
[PMID: 29501943] |
| HEK293 | IC50 |
1.61 μM
Compound: CPT
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| HEK293 | IC50 |
0.6 μM
Compound: CPT
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32668379] |
| HEK293 | IC50 |
8.75 μM
Compound: CPT
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hr by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hr by MTT assay
|
[PMID: 32682183] |
| HEK293 | IC50 |
5.6 nM
Compound: CPT
|
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
|
[PMID: 34952177] |
| HEK293 | IC50 |
0.81 μM
Compound: CPT
|
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HEK-293T | IC50 |
5.65 μM
Compound: CPT
|
Cytotoxicity against human HEK293T cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293T cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| HEK-293T | IC50 |
0.69 μM
Compound: CPT
|
Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| HEK-293T | IC50 |
0.03 μM
Compound: CPT
|
Cytotoxicity against HEK293T cells
Cytotoxicity against HEK293T cells
|
[PMID: 36924947] |
| HeLa | IC50 |
9 μM
Compound: Camptothecin
|
Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
|
[PMID: 11430001] |
| HeLa | GI50 |
0.6 μM
Compound: Camptothecin
|
Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay
Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay
|
[PMID: 15026047] |
| HeLa | IC50 |
117.2 nM
Compound: Camptothecin (table 1)
|
Concentration required to inhibit growth of human cervical HeLa carcinoma cell line
Concentration required to inhibit growth of human cervical HeLa carcinoma cell line
|
[PMID: 15454230] |
| HeLa | GI50 |
0.01 μM
Compound: camptothecin
|
Growth inhibition of HeLa cells after 4 days
Growth inhibition of HeLa cells after 4 days
|
[PMID: 17418582] |
| HeLa | IC50 |
0.5 μM
Compound: camptothecine
|
Cytotoxicity against human HeLa cells by MTT method
Cytotoxicity against human HeLa cells by MTT method
|
[PMID: 17547457] |
| HeLa | IC50 |
1.08 μM
Compound: camptothecin
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 18178085] |
| HeLa | GI50 |
0.18 μM
Compound: 1, camptothecin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 18180162] |
| HeLa | ED50 |
0.19 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 18220355] |
| HeLa | IC50 |
0.19 μg/mL
Compound: camptothecin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 18774864] |
| HeLa | IC50 |
0.072 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells by sulforhodamine B assay
Cytotoxicity against human HeLa cells by sulforhodamine B assay
|
[PMID: 19345580] |
| HeLa | IC50 |
1.22 μM
Compound: camptothecin
|
Cytotoxicity against human HeLa cells by SRB staining-based fluorescence cytometry
Cytotoxicity against human HeLa cells by SRB staining-based fluorescence cytometry
|
[PMID: 19653666] |
| HeLa | GI50 |
1.3 μM
Compound: CPT
|
Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| HeLa | GI50 |
0.04 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HeLa | IC50 |
0.2 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human HeLa cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HeLa | IC50 |
0.58 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19836231] |
| HeLa | IC50 |
0.63 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
|
[PMID: 19939682] |
| HeLa | IC50 |
1.85 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 3 days
Cytotoxicity against human HeLa cells after 3 days
|
[PMID: 19954977] |
| HeLa | IC50 |
0.86 μM
Compound: camptothecin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 20093033] |
| HeLa | IC50 |
0.63 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum
Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum
|
[PMID: 20188578] |
| HeLa | IC50 |
0.94 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 20356735] |
| HeLa | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
|
[PMID: 20392646] |
| HeLa | IC50 |
1.1 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 4 days by MTT assay
Cytotoxicity against human HeLa cells after 4 days by MTT assay
|
[PMID: 20619511] |
| HeLa | GI50 |
0.08 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| HeLa | IC50 |
0.0089 μM
Compound: 1, CPT
|
Cytotoxicity against human HeLa cells after 72 hrs by trypan blue assay
Cytotoxicity against human HeLa cells after 72 hrs by trypan blue assay
|
[PMID: 21071230] |
| HeLa | IC50 |
1.5 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21186067] |
| HeLa | GI50 |
1.3 μM
Compound: 1
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| HeLa | IC50 |
1.08 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 2 days
Cytotoxicity against human HeLa cells after 2 days
|
[PMID: 21419530] |
| HeLa | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 2 days
Cytotoxicity against human HeLa cells after 2 days
|
[PMID: 21601964] |
| HeLa | IC50 |
8.93 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay
|
[PMID: 21983445] |
| HeLa | IC50 |
1.01 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 2 days
Cytotoxicity against human HeLa cells after 2 days
|
[PMID: 22318164] |
| HeLa | IC50 |
0.4 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 48 hrs by MTS assay
Cytotoxicity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 22542106] |
| HeLa | IC50 |
1.57 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 24 hrs by MTS assay
Cytotoxicity against human HeLa cells after 24 hrs by MTS assay
|
[PMID: 22542106] |
| HeLa | IC50 |
0.4 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 48 hrs by MTS assay
Cytotoxicity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 23153813] |
| HeLa | IC50 |
1.57 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 24 hrs by MTS assay
Cytotoxicity against human HeLa cells after 24 hrs by MTS assay
|
[PMID: 23153813] |
| HeLa | GI50 |
0.05 μM
Compound: Camptothecin
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay
Growth inhibition of human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23357037] |
| HeLa | GI50 |
0.6 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 23831507] |
| HeLa | IC50 |
0.13 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells by SRB assay
Antiproliferative activity against human HeLa cells by SRB assay
|
[PMID: 24200393] |
| HeLa | IC50 |
0.5 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 24 to 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 to 72 hrs by MTT assay
|
[PMID: 24303808] |
| HeLa | IC50 |
24 nM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| HeLa | IC50 |
0.42 μM
Compound: CPT, Camptothecin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 24980118] |
| HeLa | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
|
[PMID: 25481396] |
| HeLa | IC50 |
11.62 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25599951] |
| HeLa | IC50 |
0.18 μM
Compound: camptothecin
|
Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
|
[PMID: 25936262] |
| HeLa | IC50 |
0.41 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
|
[PMID: 26022080] |
| HeLa | IC50 |
14 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26188908] |
| HeLa | IC50 |
1.59 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
|
[PMID: 26334499] |
| HeLa | IC50 |
6.13 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| HeLa | IC50 |
19.8 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
|
[PMID: 26649907] |
| HeLa | IC50 |
0.59 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
|
[PMID: 26927425] |
| HeLa | IC50 |
0.18 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
|
[PMID: 26945111] |
| HeLa | IC50 |
59.13 μM
Compound: Camptothecin
|
Growth inhibition of human HeLa cells after 72 hrs by MTT assay
Growth inhibition of human HeLa cells after 72 hrs by MTT assay
|
[PMID: 27344492] |
| HeLa | IC50 |
1.41 μM
Compound: 1; CPT
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27416553] |
| HeLa | IC50 |
0.13 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
|
[PMID: 27484510] |
| HeLa | GI50 |
0.0054 μM
Compound: CPT
|
Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay
Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay
|
[PMID: 27597409] |
| HeLa | IC50 |
0.4 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| HeLa | IC50 |
11.36 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
|
[PMID: 27667553] |
| HeLa | IC50 |
60.01 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28063351] |
| HeLa | IC50 |
0.09 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 28068603] |
| HeLa | IC50 |
0.06 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 28384547] |
| HeLa | IC50 |
0.12 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 28425292] |
| HeLa | IC50 |
10.1 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 28462840] |
| HeLa | IC50 |
3.8 μM
Compound: CPT
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 28511910] |
| HeLa | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 48 hrs by WST-1 assay
Cytotoxicity against human HeLa cells after 48 hrs by WST-1 assay
|
[PMID: 28557449] |
| HeLa | IC50 |
2.62 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 28633898] |
| HeLa | GI50 |
0.19 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| HeLa | IC50 |
1.37 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
|
[PMID: 29402741] |
| HeLa | IC50 |
0.94 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay
Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay
|
[PMID: 29407986] |
| HeLa | IC50 |
0.13 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
|
[PMID: 29510948] |
| HeLa | IC50 |
1.3 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 30007563] |
| HeLa | IC50 |
>50 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| HeLa | IC50 |
0.66 μM
Compound: CPT
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| HeLa | IC50 |
1.37 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
|
[PMID: 30262132] |
| HeLa | IC50 |
6.51 μM
Compound: CPT
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| HeLa | IC50 |
0.5 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
|
[PMID: 31398033] |
| HeLa | IC50 |
6 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
|
[PMID: 32526552] |
| HeLa | IC50 |
1.66 μM
Compound: Camptothecin
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 32932211] |
| HeLa | IC50 |
0.23 μM
Compound: CPT
|
Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34678573] |
| HeLa | IC50 |
8.28 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34852457] |
| HeLa | GI50 |
0.6 μM
Compound: Camptothecin
|
Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
|
[PMID: 37531922] |
| HeLa | IC50 |
>300 μM
Compound: CPT
|
Cytostatic activity against human HeLa cells after 24 hrs by CCK-8 assay
Cytostatic activity against human HeLa cells after 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| HeLa | IC50 |
8.9 ng/mL
Compound: 1; CPT
|
Cytotoxicity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| HeLa | IC50 |
8.9 nM
Compound: 1; CPT
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 38421819] |
| HeLa | IC50 |
0.108 μM
Compound: CPT
|
Cytotoxicity against human HeLa cells measured after 72 hrs
Cytotoxicity against human HeLa cells measured after 72 hrs
|
[PMID: 38716896] |
| HeLa | IC50 |
127 μM
Compound: Camptothecin
|
Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells
Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells
|
[PMID: 7699697] |
| HeLa | IC50 |
0.28 μg/mL
Compound: Camptothecin
|
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
|
10.1007/s00044-010-9381-7 |
| HeLa | IC50 |
0.18 μM
Compound: CPT
|
Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| Hep 3B2 | GI50 |
0.01 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| Hep 3B2 | IC50 |
0.06 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human Hep3B cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| Hep 3B2 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| Hep 3B2 | IC50 |
434.29 nM
Compound: CPT
|
Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth
Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth
|
[PMID: 37806498] |
| Hep 3B2 | IC50 |
>300 μM
Compound: CPT
|
Antiproliferative activity against human Hep3B cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Hep3B cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| Hep 3B2 | IC50 |
>300 μM
Compound: CPT
|
Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 12.5 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diph
Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 12.5 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diph
|
[PMID: 38278140] |
| Hep 3B2 | IC50 |
>300 μM
Compound: CPT
|
Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 25 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphen
Antiproliferative activity against human Hep3B cells incubated for 24 hrs in presence of 25 uM (2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphen
|
[PMID: 38278140] |
| Hep 3B2 | IC50 |
102.9 μM
Compound: CPT
|
Antiproliferative activity against human Hep3B cells at 2:1 compound:(2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphenyl-ethyl]amino]-1-(1H-indo
Antiproliferative activity against human Hep3B cells at 2:1 compound:(2R)-2,6-diamino-N-[(1R)-5-amino-1-[[(1R)-2-[[(1R)-2-[[(1R)-5-amino-1-[[(1R)-5-amino-1-[[(1R)-2-[[(1R)-1-[[(1R)-5-amino-1-carbamoyl-pentyl]carbamoyl]-2,2-diphenyl-ethyl]amino]-1-(1H-indo
|
[PMID: 38278140] |
| HEp-2 | ED50 |
0.02 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human Hep2 cells by MTT assay
Cytotoxicity against human Hep2 cells by MTT assay
|
[PMID: 18220355] |
| HEp-2 | IC50 |
0.02 μg/mL
Compound: camptothecin
|
Cytotoxicity against human Hep2 cells by MTT assay
Cytotoxicity against human Hep2 cells by MTT assay
|
[PMID: 18774864] |
| HEp-2 | IC50 |
0.7 μM
Compound: Camptothecin
|
Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| HEp-2 | IC50 |
3.04 μM
Compound: CPT
|
Cytotoxicity against human Hep2 cells measured after 72 hrs by MTT assay
Cytotoxicity against human Hep2 cells measured after 72 hrs by MTT assay
|
[PMID: 27721148] |
| HEp-2 | IC50 |
3.04 μM
Compound: CPT
|
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28923388] |
| HEp-2 | IC50 |
3.01 μM
Compound: CPT
|
Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| HepG2 | IC50 |
6.3 nM
Compound: 1
|
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human hepatocellular cells (HepG2)
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]thymidine into cellular DNA of human hepatocellular cells (HepG2)
|
[PMID: 10479293] |
| HepG2 | IC50 |
0.03 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 17254669] |
| HepG2 | IC50 |
0.13 μM
Compound: 1, CPT
|
Cytotoxicity against human HepG2 cells after 4 days by MTT assay
Cytotoxicity against human HepG2 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| HepG2 | IC50 |
0.3 μM
Compound: camptothecin
|
Cytotoxicity against human HEPG2 cells by MTT assay
Cytotoxicity against human HEPG2 cells by MTT assay
|
[PMID: 18841903] |
| HepG2 | IC50 |
455 nM
Compound: camptothecin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| HepG2 | GI50 |
0.1 μM
Compound: 1, CPT
|
Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HepG2 | IC50 |
0.2 μM
Compound: 1, CPT
|
Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HepG2 | IC50 |
0.06 μM
Compound: camptothecin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 19863101] |
| HepG2 | CC50 |
0.02 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| HepG2 | IC50 |
0.02 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 96 hrs
Cytotoxicity against human HepG2 cells after 96 hrs
|
[PMID: 22276775] |
| HepG2 | IC50 |
6.4 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 22326393] |
| HepG2 | IC50 |
<0.1 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 22409771] |
| HepG2 | GI50 |
0.22 μM
Compound: 1, CPT
|
Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| HepG2 | IC50 |
0.01 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| HepG2 | CC50 |
0.04 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| HepG2 | IC50 |
32.3 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 23562244] |
| HepG2 | IC50 |
0.2 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 24041234] |
| HepG2 | IC50 |
0.6 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells after 24 to 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 to 72 hrs by MTT assay
|
[PMID: 24303808] |
| HepG2 | IC50 |
0.05 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 24360564] |
| HepG2 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| HepG2 | IC50 |
29.81 μM
Compound: Camptothecin
|
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27344492] |
| HepG2 | IC50 |
1.52 μM
Compound: 1; CPT
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 27416553] |
| HepG2 | IC50 |
4.92 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28511910] |
| HepG2 | IC50 |
0.43 μM
Compound: Camp
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| HepG2 | IC50 |
4.37 μM
Compound: Camp
|
Induction of apoptosis in human HepG2 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
Induction of apoptosis in human HepG2 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
|
[PMID: 29223099] |
| HepG2 | IC50 |
0.5 μM
Compound: Camptothecin
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 30007563] |
| HepG2 | IC50 |
13.2 μM
Compound: Camptothecin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30025344] |
| HepG2 | IC50 |
0.37 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30055465] |
| HepG2 | IC50 |
1.36 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| HepG2 | IC50 |
6.08 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30125725] |
| HepG2 | IC50 |
0.66 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 30600208] |
| HepG2 | IC50 |
4.79 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| HepG2 | IC50 |
5.69 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30875505] |
| HepG2 | IC50 |
0.4 μM
Compound: CPT
|
Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antitumor activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 32668379] |
| HepG2 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| HepG2 | IC50 |
0.11 μM
Compound: 1; CPT
|
Antiproliferative activity against human HepG2 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| HepG2 | IC50 |
3.5 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34852457] |
| HepG2 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HepG2 | IC50 |
0.02 μM
Compound: CPT
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 36924947] |
| HepG2 | IC50 |
0.04 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HepG2 | IC50 |
33.16 nM
Compound: CPT
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth
|
[PMID: 37806498] |
| HepG2 | IC50 |
1.36 μM
Compound: Camptothecin
|
Antiproliferative activity against human HepG2 cells assessed reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 38107170] |
| HepG2 | IC50 |
13.2 μM
Compound: Camptothecin
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by alamarBlue assay
|
[PMID: 38107170] |
| HepG2 | IC50 |
1.8 μM
Compound: CPT
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| HepG2 | IC50 |
7.25 ng/mL
Compound: 1; CPT
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| HepG2 | IC50 |
7.25 nM
Compound: 1; CPT
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 38421819] |
| HepG2 | IC50 |
0.09 μg/mL
Compound: 1
|
Cytotoxicity in HepG2-T14 cancer cell line
Cytotoxicity in HepG2-T14 cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| HepG2 | IC50 |
0.2 μM
Compound: Camptothecin
|
Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| HFL1 | IC50 |
1.06 μM
Compound: Camptothecin
|
Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| HGC-27 | IC50 |
>150 μM
Compound: CPT
|
Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HGC-27 | IC50 |
0.166 μM
Compound: CPT
|
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 35868003] |
| HL-60 | IC50 |
0.066 μM
Compound: Camptothecin
|
In vitro antiproliferative activity of compound against HL-60 (human assay
In vitro antiproliferative activity of compound against HL-60 (human assay
|
[PMID: 12639541] |
| HL-60 | IC50 |
130 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 15974606] |
| HL-60 | GI50 |
0.03 μM
Compound: camptothecin
|
Growth inhibition of human HL60 cells by Almar blue assay
Growth inhibition of human HL60 cells by Almar blue assay
|
[PMID: 17418582] |
| HL-60 | IC50 |
0.018 μM
Compound: camptothecin
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 17498951] |
| HL-60 | GI50 |
1.7 nM
Compound: CPT, camptothecin
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 17962028] |
| HL-60 | IC50 |
0.013 μM
Compound: camptothecin
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 18178085] |
| HL-60 | IC50 |
0.089 μM
Compound: CPT
|
Cytotoxicity against human HL60 cells by sulforhodamine B assay
Cytotoxicity against human HL60 cells by sulforhodamine B assay
|
[PMID: 19345580] |
| HL-60 | IC50 |
0.8 μM
Compound: camptothecin
|
Cytotoxicity against human HL60 cells by rapid colorimetric assay
Cytotoxicity against human HL60 cells by rapid colorimetric assay
|
[PMID: 19585998] |
| HL-60 | IC50 |
6 nM
Compound: camptothecin
|
Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| HL-60 | IC50 |
0.067 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 19836231] |
| HL-60 | IC50 |
0.065 μM
Compound: camptothecin
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 20093033] |
| HL-60 | IC50 |
0.59 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 20356735] |
| HL-60 | IC50 |
0.1 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
|
[PMID: 20392646] |
| HL-60 | IC50 |
0.017 μM
Compound: 1, CPT
|
Cytotoxicity against human HL60 cells after 72 hrs by trypan blue assay
Cytotoxicity against human HL60 cells after 72 hrs by trypan blue assay
|
[PMID: 21071230] |
| HL-60 | IC50 |
0.018 μM
Compound: 1, CPT
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 21095131] |
| HL-60 | IC50 |
0.018 μM
Compound: CPT
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 21353568] |
| HL-60 | IC50 |
0.065 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 2 days
Cytotoxicity against human HL60 cells after 2 days
|
[PMID: 21419530] |
| HL-60 | IC50 |
0.1 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 2 days
Cytotoxicity against human HL60 cells after 2 days
|
[PMID: 21601964] |
| HL-60 | IC50 |
0.6 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 2 days by MTT assay
Cytotoxicity against human HL60 cells after 2 days by MTT assay
|
[PMID: 22325897] |
| HL-60 | GI50 |
<0.003 μM
Compound: 1, CPT
|
Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| HL-60 | IC50 |
0.06 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 24041234] |
| HL-60 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 25599951] |
| HL-60 | IC50 |
0.015 μM
Compound: CPT
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 26188908] |
| HL-60 | IC50 |
0.035 μM
Compound: Camptothecin
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay
|
[PMID: 27096049] |
| HL-60 | IC50 |
0.019 μM
Compound: Camptothecin
|
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay
|
[PMID: 27318980] |
| HL-60 | IC50 |
0.019 μM
Compound: Camptothecin
|
Antiproliferative activity against human HL60 cells measured after 48 hrs by WST1 assay
Antiproliferative activity against human HL60 cells measured after 48 hrs by WST1 assay
|
[PMID: 28477443] |
| HL-60 | IC50 |
0.92 μM
Compound: Camptothecin
|
Antiproliferative activity against human HL60 cells after 72 hrs by tryphan blue staining based hematocytometric method
Antiproliferative activity against human HL60 cells after 72 hrs by tryphan blue staining based hematocytometric method
|
[PMID: 29131616] |
| HL-60 | IC50 |
0.02 μM
Compound: Camp
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| HL-60 | IC50 |
0.07 μM
Compound: Camp
|
Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
Induction of apoptosis in human HL60 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
|
[PMID: 29223099] |
| HL-60 | IC50 |
0.0067 μM
Compound: Camptothecin
|
Antiproliferative activity against human HL60 cells
Antiproliferative activity against human HL60 cells
|
[PMID: 29429833] |
| HL-60 | IC50 |
0.42 μM
Compound: Camptothecin
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| HL-60 | IC50 |
<0.064 μM
Compound: CPT; 1
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 30509782] |
| HL-60 | IC50 |
0.018 μM
Compound: Camptothecin
|
Antiproliferation activity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferation activity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 32201190] |
| HL-60 | IC50 |
1.7 μM
Compound: Camptothecin
|
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 33161122] |
| HL-60 | IC50 |
0.91 μM
Compound: Camptothecin
|
Antitumor activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| HL-60 | IC50 |
0.68 μM
Compound: 1
|
Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells
Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells
|
[PMID: 8410981] |
| HL-60 | IC50 |
5 nM
Compound: CPT
|
Tested in vitro for growth inhibitory activity against HL60 (human promyelocytic leukemic) cells
Tested in vitro for growth inhibitory activity against HL60 (human promyelocytic leukemic) cells
|
10.1016/S0960-894X(97)10181-0 |
| HL60/MX2 | GI50 |
1.5 nM
Compound: CPT, camptothecin
|
Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay
Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay
|
[PMID: 17962028] |
| HOC-21 cell line | IC50 |
14.7 ng/mL
Compound: 1a
|
Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay
Tested in vitro for the inhibition of HOC-21(human ovarian cancer) cell line by MTT assay
|
[PMID: 7932525] |
| HOP-62 | GI50 |
0.01 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line
Antiproliferative activity was determined for 50% growth inhibition against human lung HOP-62 cell line
|
[PMID: 11020283] |
| HOP-62 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibitory activity against human lung HOP-62 cell line
Growth inhibitory activity against human lung HOP-62 cell line
|
[PMID: 15509164] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human HOP62 cell line
Antiproliferative activity against human HOP62 cell line
|
[PMID: 16442283] |
| HOP-62 | GI50 |
0.01 μM
Compound: 2
|
Antiproliferative activity against human HOP62 cell line
Antiproliferative activity against human HOP62 cell line
|
[PMID: 16913702] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 17402722] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 17676830] |
| HOP-62 | GI50 |
0.01 μM
Compound: 2
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 17696418] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human HOP62 cells
Antiproliferative activity against human HOP62 cells
|
[PMID: 18630891] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 19783447] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1, CPT
|
Antiproliferative activity against human HOP62 cells
Antiproliferative activity against human HOP62 cells
|
[PMID: 20155916] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 20630766] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human HOP62 cells by SRB assay
Antiproliferative activity against human HOP62 cells by SRB assay
|
[PMID: 21710981] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| HOP-62 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells by SRB assay
Cytotoxicity against human HOP62 cells by SRB assay
|
[PMID: 24502276] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Growth inhibition of human HOP62 cells after 48 hrs by SRB assay
Growth inhibition of human HOP62 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human HOP62 cells after 48 hrs
Antiproliferative activity against human HOP62 cells after 48 hrs
|
[PMID: 27070999] |
| HOP-62 | GI50 |
<0.01 μM
Compound: 18
|
Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| HOP-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human HOP62 cells assessed as growth inhibition
Antiproliferative activity against human HOP62 cells assessed as growth inhibition
|
[PMID: 28657311] |
| HOS | IC50 |
0.049 μM
Compound: CPT
|
Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HOS cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| Hs 683 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Growth inhibition of human Hs683 cells after 72 hrs by MTT assay
Growth inhibition of human Hs683 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| HT-1080 | IC50 |
0.08 μM
Compound: camptothecin
|
Cytotoxicity against human HT1080 cells by SRB assay
Cytotoxicity against human HT1080 cells by SRB assay
|
[PMID: 17498951] |
| HT-1080 | IC50 |
0.08 μM
Compound: 1, CPT
|
Cytotoxicity against human HT1080 cells
Cytotoxicity against human HT1080 cells
|
[PMID: 21095131] |
| HT-1080 | IC50 |
0.08 μM
Compound: CPT
|
Cytotoxicity against human HT1080 cells by MTT assay
Cytotoxicity against human HT1080 cells by MTT assay
|
[PMID: 21353568] |
| HT-29 | IC50 |
80 nM
Compound: CPT
|
Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay
Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| HT-29 | IC50 |
1.4 μM
Compound: Camptothecin
|
In vitro antiproliferative activity of compound against HT-29 (human colon caner ) cell line aws determined by SRB assay
In vitro antiproliferative activity of compound against HT-29 (human colon caner ) cell line aws determined by SRB assay
|
[PMID: 12639541] |
| HT-29 | IC50 |
30 nM
Compound: camptothecin
|
Antiproliferative activity against human HT29 cell line
Antiproliferative activity against human HT29 cell line
|
[PMID: 16686539] |
| HT-29 | IC50 |
0.014 μM
Compound: camptothecin
|
Growth inhibition of human HT29 cells by neutral red assay
Growth inhibition of human HT29 cells by neutral red assay
|
[PMID: 17204425] |
| HT-29 | IC50 |
3.16 μM
Compound: 1, CPT
|
Cytotoxicity against human HT29 cells after 1 hr
Cytotoxicity against human HT29 cells after 1 hr
|
[PMID: 18419110] |
| HT-29 | IC50 |
8.81 μM
Compound: 1, CPT
|
Cytotoxicity against human mitoxantrone-resistant HT29 cells after 1 hr
Cytotoxicity against human mitoxantrone-resistant HT29 cells after 1 hr
|
[PMID: 18419110] |
| HT-29 | IC50 |
3.16 μM
Compound: 1, camptothecin, CPT
|
Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs
Antiproliferative activity against human HT29 cells after 1 hr of drug exposure measured after 72 hrs
|
[PMID: 18424133] |
| HT-29 | IC50 |
8.81 μM
Compound: 1, camptothecin, CPT
|
Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs
Antiproliferative activity against BCRP overexpressing mitoxantrone-resistant human HT29 cells after 1 hr of drug exposure measured after 72 hrs
|
[PMID: 18424133] |
| HT-29 | IC50 |
0.09 μM
Compound: 1, CPT
|
Cytotoxicity against human HT29 cells after 4 days by MTT assay
Cytotoxicity against human HT29 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| HT-29 | IC50 |
2 μM
Compound: camptothecin
|
Cytotoxicity against human HT29 cells by MTT assay
Cytotoxicity against human HT29 cells by MTT assay
|
[PMID: 18841903] |
| HT-29 | IC50 |
0.12 μM
Compound: 1, CPT
|
Antitumor activity against human HT-29 cells by SRB method
Antitumor activity against human HT-29 cells by SRB method
|
[PMID: 19541483] |
| HT-29 | IC50 |
1.22 μM
Compound: camptothecin
|
Cytotoxicity against human HT-29 cells by SRB staining-based fluorescence cytometry
Cytotoxicity against human HT-29 cells by SRB staining-based fluorescence cytometry
|
[PMID: 19653666] |
| HT-29 | GI50 |
0.03 μM
Compound: 1, CPT
|
Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HT-29 | IC50 |
0.4 μM
Compound: 1, CPT
|
Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
Cytotoxicity against human HT-29 cells expressing p53 mutant after 48 hrs by SRB assay
|
[PMID: 19715319] |
| HT-29 | IC50 |
1.07 μM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 19836231] |
| HT-29 | ED50 |
0.06 μM
Compound: camptothecin
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 19839614] |
| HT-29 | IC50 |
0.85 μM
Compound: camptothecin
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 20093033] |
| HT-29 | EC50 |
60 nM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 20825206] |
| HT-29 | ED50 |
0.06 μM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 20939540] |
| HT-29 | GI50 |
0.05 μM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| HT-29 | IC50 |
260 nM
Compound: 1a
|
Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| HT-29 | IC50 |
10 μM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 21843907] |
| HT-29 | GI50 |
0.05 μM
Compound: Camptothecin
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| HT-29 | IC50 |
0.7 nM
Compound: Camptothecin
|
Antiproliferative activity against human HT-29 cells by SRB assay
Antiproliferative activity against human HT-29 cells by SRB assay
|
[PMID: 24200393] |
| HT-29 | IC50 |
0.06 μM
Compound: CPT
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 24360564] |
| HT-29 | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HT-29 | IC50 |
>100 μM
Compound: CPT
|
Cytotoxicity against human HT-29 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| HT-29 | IC50 |
>150 μM
Compound: CPT
|
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HT-29 | IC50 |
1.37 μM
Compound: CPT
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 35868003] |
| HT-29 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 36924947] |
| HT-29 | IC50 |
0.19 μM
Compound: CPT
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| HT-29 | IC50 |
2.35 μM
Compound: CPT
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38128233] |
| HT-29 | IC50 |
1.87 μM
Compound: CPT
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| HT-29 | IC50 |
46 nM
Compound: 1
|
Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay
|
[PMID: 7853331] |
| HT-29 | IC50 |
0.0878 μM
Compound: Camptothecin
|
Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.
|
[PMID: 9003520] |
| Huh-7 | IC50 |
<0.1 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
|
[PMID: 22409771] |
| Huh-7 | IC50 |
0.15 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human HuH7 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| Huh-7 | IC50 |
0.06 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells after 3 days by SRB assay
Cytotoxicity against human HuH7 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| Huh-7 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay
|
[PMID: 25247770] |
| Huh-7 | IC50 |
≤0.1 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| Huh-7 | GI50 |
0.006 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710] |
| Huh-7 | GI50 |
0.099 μM
Compound: 1
|
Growth inhibition of human HuH7 cells after 72 hrs by MTT assay
Growth inhibition of human HuH7 cells after 72 hrs by MTT assay
|
[PMID: 30336023] |
| Huh-7 | IC50 |
0.0023 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells by MTT assay
Cytotoxicity against human HuH7 cells by MTT assay
|
[PMID: 30543429] |
| Huh-7 | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human HuH7 cells after 48 hrs by CCK8 assay
Cytotoxicity against human HuH7 cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| Huh-7 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| Huh-7 | IC50 |
113.1 μM
Compound: CPT
|
Antiproliferative activity against human Huh-7 cells incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Huh-7 cells incubated for 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| Huh-7 | IC50 |
0.1 μM
Compound: CPT
|
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation by sulforhodamine B assay
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation by sulforhodamine B assay
|
10.1039/C4MD00306C |
| HUVEC | ED50 |
258 nM
Compound: camptothecin
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043407] |
| HUVEC | IC50 |
0.2 μM
Compound: Camptothecin
|
Toxicity against HUVEC incubated for 48 hrs by MTT assay
Toxicity against HUVEC incubated for 48 hrs by MTT assay
|
[PMID: 25590864] |
| HUVEC | IC50 |
0.01 μM
Compound: CPT
|
Cytotoxicity against human HUVEC cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HUVEC cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| HUVEC | IC50 |
0.012 μM
Compound: CPT
|
In-vitro cytotoxic activity against human HUVEC cells incubated for 72 hrs by CCK8 assay
In-vitro cytotoxic activity against human HUVEC cells incubated for 72 hrs by CCK8 assay
|
[PMID: 35550978] |
| HUVEC | IC50 |
0.06 μM
Compound: CPT
|
Cytotoxicity against HUVEC cells
Cytotoxicity against HUVEC cells
|
[PMID: 36924947] |
| HUVEC | IC50 |
0.04 μM
Compound: CPT
|
Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| IGROV-1 | IC50 |
0.012 μM
Compound: 1, CPT
|
Cytotoxicity against human IGROV1 cells after 72 hrs
Cytotoxicity against human IGROV1 cells after 72 hrs
|
[PMID: 18419110] |
| IGROV-1 | IC50 |
1.65 μM
Compound: 1, CPT
|
Cytotoxicity against human IGROV1 cells after 1 hr
Cytotoxicity against human IGROV1 cells after 1 hr
|
[PMID: 18419110] |
| IMR-32 | IC50 |
2.21 nM
Compound: Camptothecin
|
Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors
Cytotoxic activity against human neuroblastoma IMR32 cells which over-express somatostatin receptors
|
[PMID: 12617894] |
| IMR-32 | IC50 |
0.08 μM
Compound: Camptothecin
|
Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| IMR-90 | IC50 |
0.43 μM
Compound: Camptothecin
|
Cytotoxicity against human IMR90 cells incubated for 3 days by SRB assay
Cytotoxicity against human IMR90 cells incubated for 3 days by SRB assay
|
[PMID: 22863526] |
| Jurkat | IC50 |
5.6 nM
Compound: Camptothecin
|
Inhibitory activity against Jurkat human leukemia cells
Inhibitory activity against Jurkat human leukemia cells
|
[PMID: 11384245] |
| Jurkat | IC50 |
5.6 nM
Compound: Camptothecin
|
Growth inhibitory activity against human Jurkat leukemia cell line (JLC)
Growth inhibitory activity against human Jurkat leukemia cell line (JLC)
|
[PMID: 12620081] |
| Jurkat | IC50 |
1.4 nM
Compound: camptothecin
|
Growth inhibition of human Jurkat cells after 96 hrs
Growth inhibition of human Jurkat cells after 96 hrs
|
[PMID: 18061452] |
| Jurkat | GI50 |
0.09 μM
Compound: 1
|
Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| Jurkat | IC50 |
0.026 μM
Compound: Camptothecin
|
Cytotoxicity against human Jurkat cells after 2 days by MTT assay
Cytotoxicity against human Jurkat cells after 2 days by MTT assay
|
[PMID: 22325897] |
| Jurkat | IC50 |
0.11 μM
Compound: CPT, Camptothecin
|
Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay
Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay
|
[PMID: 24980118] |
| Jurkat | IC50 |
0.085 μM
Compound: CPT
|
Anticancer activity against human Jurkat cells after 48 hrs by MTT assay
Anticancer activity against human Jurkat cells after 48 hrs by MTT assay
|
[PMID: 26890120] |
| Jurkat | GI50 |
0.06 μM
Compound: Camptothecin
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| Jurkat | IC50 |
22 μM
Compound: CPT
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 30853330] |
| Jurkat | IC50 |
51.5 μM
Compound: CPT
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell proliferation measured after 24 hrs by MTT assay
|
[PMID: 30853330] |
| Jurkat | IC50 |
22 μM
Compound: Camptophecin
|
Cytotoxicity against human Jurkat cells
Cytotoxicity against human Jurkat cells
|
[PMID: 33421712] |
| Jurkat | IC50 |
0.1 μM
Compound: 1; CPT
|
Anticancer activity against human Jurkat cells incubated for 48 hrs by MTT assay
Anticancer activity against human Jurkat cells incubated for 48 hrs by MTT assay
|
[PMID: 34175539] |
| K562 | IC50 |
0.04 μM
Compound: camptothecin
|
Growth inhibition of K562 cells by XTT assay after 5 days
Growth inhibition of K562 cells by XTT assay after 5 days
|
[PMID: 17411092] |
| K562 | IC50 |
0.04 μM
Compound: camptothecin
|
Cytotoxicity against human K562 cells after 5 days by XTT assay
Cytotoxicity against human K562 cells after 5 days by XTT assay
|
[PMID: 18076140] |
| K562 | IC50 |
1.4 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human K562 cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| K562 | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
|
[PMID: 19939682] |
| K562 | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum
Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum
|
[PMID: 20188578] |
| K562 | IC50 |
2 nM
Compound: camptothecin
|
Cytotoxicity against human imitinib-resistant K562 cells by MTT assay
Cytotoxicity against human imitinib-resistant K562 cells by MTT assay
|
[PMID: 20329739] |
| K562 | IC50 |
2 nM
Compound: camptothecin
|
Cytotoxicity against imatinib-resistant human K562 cells after 72 hrs by MTT assay
Cytotoxicity against imatinib-resistant human K562 cells after 72 hrs by MTT assay
|
[PMID: 20590148] |
| K562 | GI50 |
0.06 μM
Compound: CPT
|
Cytotoxicity against human K562 cells after 72 hrs by XTT assay
Cytotoxicity against human K562 cells after 72 hrs by XTT assay
|
[PMID: 20591678] |
| K562 | GI50 |
0.06 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| K562 | IC50 |
0.59 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells by MTT assay
Cytotoxicity against human K562 cells by MTT assay
|
[PMID: 21115246] |
| K562 | IC50 |
1.18 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells after 2 days
Cytotoxicity against human K562 cells after 2 days
|
[PMID: 22318164] |
| K562 | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human K562 cells after 24 to 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 to 72 hrs by MTT assay
|
[PMID: 24303808] |
| K562 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 24360564] |
| K562 | IC50 |
31 nM
Compound: CPT
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| K562 | IC50 |
0.13 μM
Compound: Camptothecin
|
Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay
Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay
|
[PMID: 25590864] |
| K562 | IC50 |
5.37 μM
Compound: CPT
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25599951] |
| K562 | IC50 |
<0.003 μM
Compound: CPT
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| K562 | IC50 |
0.09 μM
Compound: Camp
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| K562 | IC50 |
0.711 μM
Compound: Camp
|
Induction of apoptosis in human K562 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
Induction of apoptosis in human K562 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
|
[PMID: 29223099] |
| K562 | IC50 |
0.07 μM
Compound: CPT
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 30055465] |
| K562 | IC50 |
<0.003 μM
Compound: CPT
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| K562 | IC50 |
2.69 μM
Compound: Camptothecin
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
|
[PMID: 32526552] |
| K562 | IC50 |
0.32 μM
Compound: CPT
|
Cytotoxicity against human K562 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| K562 | IC50 |
0.58 μM
Compound: Camptothecin
|
Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| K562 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against human K562 cells by MTT assay
Cytotoxicity against human K562 cells by MTT assay
|
[PMID: 36924947] |
| K562 | IC50 |
0.08 μM
Compound: CPT
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| K562 | GI50 |
54.3 ng/mL
Compound: 1; CPT
|
Growth inhibition of human K562 cells incubated for 72 hrs by MTT assay
Growth inhibition of human K562 cells incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| K562 | IC50 |
2 nM
Compound: 1; CPT
|
Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38421819] |
| K562 | IC50 |
57 nM
Compound: CPT
|
Antiproliferative activity measured against K562adr leukemia cells.
Antiproliferative activity measured against K562adr leukemia cells.
|
[PMID: 9876111] |
| KB | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against drug-resistant tumor cell line KBV20C.
Antiproliferative activity against drug-resistant tumor cell line KBV20C.
|
[PMID: 10411476] |
| KB | IC50 |
0.035 μM
Compound: Camptothecin
|
Antiproliferative activity against drug-resistant tumor cell line KB7D.
Antiproliferative activity against drug-resistant tumor cell line KB7D.
|
[PMID: 10411476] |
| KB | IC50 |
0.04 μM
Compound: Camptothecin
|
Antiproliferative activity against drug-resistant tumor cell line KBwt.
Antiproliferative activity against drug-resistant tumor cell line KBwt.
|
[PMID: 10411476] |
| KB | IC50 |
0.07 μM
Compound: Camptothecin
|
Antiproliferative activity against drug-resistant tumor cell line KBMDR.
Antiproliferative activity against drug-resistant tumor cell line KBMDR.
|
[PMID: 10411476] |
| KB | IC50 |
1.04 μM
Compound: Camptothecin
|
Antiproliferative activity against drug-resistant tumor cell line KBCamp.
Antiproliferative activity against drug-resistant tumor cell line KBCamp.
|
[PMID: 10411476] |
| KB | EC50 |
0.01 μg/mL
Compound: camptothecin
|
Cytotoxicity against human KB cells after 72 hrs by MTS method
Cytotoxicity against human KB cells after 72 hrs by MTS method
|
[PMID: 11858737] |
| KB | IC50 |
28.7 nM
Compound: Camptothecin
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 11858760] |
| KB | IC50 |
0.009 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx)
In vitro cytotoxicity against KB (human epidermoid carcinoma of the nasopharynx)
|
[PMID: 14552770] |
| KB | ED50 |
22 nM
Compound: camptothecin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15043407] |
| KB | IC50 |
<0.005 μg/mL
Compound: 1 Camptothecin
|
In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay
In vitro cytotoxicity against KB cell line (human epidermoid carcinoma of the nasopharynx) using MTT assay
|
[PMID: 15225719] |
| KB | EC50 |
0.01 μg/mL
Compound: camptothecin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15270571] |
| KB | IC50 |
0.02 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1
Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1
|
[PMID: 15482929] |
| KB | ED50 |
20.9 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 17350834] |
| KB | EC50 |
0.0036 μM
Compound: camptothecin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 17552563] |
| KB | IC50 |
0.003 μM
Compound: 1, CPT
|
Cytotoxicity against human KB cells after 4 days by MTT assay
Cytotoxicity against human KB cells after 4 days by MTT assay
|
[PMID: 18554906] |
| KB | IC50 |
1.22 μM
Compound: camptothecin
|
Cytotoxicity against human KB cells by SRB staining-based fluorescence cytometry
Cytotoxicity against human KB cells by SRB staining-based fluorescence cytometry
|
[PMID: 19653666] |
| KB | IC50 |
38 nM
Compound: camptothecin
|
Cytotoxicity against human KB cells after 72 hrs by MTS assay
Cytotoxicity against human KB cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| KB | IC50 |
<0.013 μM
Compound: CPT
|
Cytotoxicity against human KB cells after 3 days by MTT assay
Cytotoxicity against human KB cells after 3 days by MTT assay
|
[PMID: 20392545] |
| KB | IC50 |
8.8 nM
Compound: CPT
|
Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay
Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay
|
[PMID: 22698783] |
| KB | IC50 |
0.121 μM
Compound: 1, CPT
|
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
|
[PMID: 23102893] |
| KB | IC50 |
0.02 μM
Compound: Camptothecin
|
Antiproliferative activity against human KB cells by SRB assay
Antiproliferative activity against human KB cells by SRB assay
|
[PMID: 24200393] |
| KB | IC50 |
0.037 μM
Compound: 1, CPT
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 25003995] |
| KB | IC50 |
0.037 μM
Compound: 1
|
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 26994847] |
| KB | IC50 |
50 nM
Compound: 1; CPT
|
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 28285912] |
| KB | IC50 |
50 nM
Compound: 1
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 28927790] |
| KB | ED50 |
2.3 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7130986] |
| KB | IC50 |
0.01 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 8759170] |
| KB | IC50 |
0.008 μM
Compound: Camptothecin
|
Inhibitory concentration that reduced the viability of KB cell population by 50%.
Inhibitory concentration that reduced the viability of KB cell population by 50%.
|
[PMID: 9003520] |
| KB | CC50 |
0.006 μM
Compound: Camptothecin
|
Compound concentration required to reduce the exponential growth of KB cells by 50%
Compound concentration required to reduce the exponential growth of KB cells by 50%
|
[PMID: 9767632] |
| KB | IC50 |
0.01 μg/mL
Compound: 1
|
Cytotoxicity in KB cancer cell line
Cytotoxicity in KB cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| KB | IC50 |
0.04 μg/mL
Compound: 1
|
Cytotoxicity in KB VP-16 R cancer cell line
Cytotoxicity in KB VP-16 R cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| KB 3-1 | IC50 |
0.01 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in KB3-1 tumor cell line
Concentration required to inhibit cell proliferation in KB3-1 tumor cell line
|
[PMID: 15482929] |
| KB 3-1 | IC50 |
0.02 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP
Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP
|
[PMID: 15482929] |
| KB 3-1 | IC50 |
0.015 μM
Compound: CPT
|
Cytotoxicity against human KB3-1 cells after 4 days by MTT assay
Cytotoxicity against human KB3-1 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| KB 3-1 | IC50 |
0.015 μM
Compound: CPT
|
Cytotoxicity against human KB3-1 cells by MTT method
Cytotoxicity against human KB3-1 cells by MTT method
|
[PMID: 18771930] |
| KB VCR R | IC50 |
0.009 μM
Compound: 1 (Camptothecin)
|
In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line)
In vitro cytotoxicity against KB/VCR (Vincristine-resistant cancer cell line)
|
[PMID: 14552770] |
| KB VCR R | IC50 |
0.03 μg/mL
Compound: 1
|
Cytotoxicity in KB VCR R cancer cell line
Cytotoxicity in KB VCR R cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| KB-V1 | IC50 |
0.025 μM
Compound: CPT
|
Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay
Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| KB-V1 | IC50 |
0.025 μM
Compound: CPT
|
Cytotoxicity against human KBV1 cells by MTT method
Cytotoxicity against human KBV1 cells by MTT method
|
[PMID: 18771930] |
| KG-1 | IC50 |
1.6 μM
Compound: Camptothecin
|
Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 33161122] |
| KG-1 | IC50 |
2.31 μM
Compound: Camptothecin
|
Antitumor activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| L02 | IC50 |
2.15 μM
Compound: CPT
|
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30875505] |
| L02 | IC50 |
>150 μM
Compound: CPT
|
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| L02 | IC50 |
0.14 μM
Compound: CPT
|
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| L02 | IC50 |
0.59 μM
Compound: CPT
|
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| L1210 | IC50 |
0.03 μM
Compound: Camptothecin
|
Inhibitory concentration required against L1210 leukemia cells
Inhibitory concentration required against L1210 leukemia cells
|
[PMID: 12182872] |
| L1210 | IC50 |
0.33 μM
Compound: CPT
|
Inhibitory concentration against L1210 leukemia cell proliferation
Inhibitory concentration against L1210 leukemia cell proliferation
|
[PMID: 12873503] |
| L1210 | IC50 |
0.06 μM
Compound: CPT
|
In vitro cytotoxic activity of compound against mouse leukemia L1210 cell line
In vitro cytotoxic activity of compound against mouse leukemia L1210 cell line
|
[PMID: 15081041] |
| L1210 | IC50 |
23 nM
Compound: 1 (Camptothecin)
|
Inhibitory activity in mice bearing L1210 leukemia
Inhibitory activity in mice bearing L1210 leukemia
|
[PMID: 1846923] |
| L1210 | IC50 |
0.03 μM
Compound: 1, CPT, NSC-100880
|
Cytotoxicity against mouse L1210 cells
Cytotoxicity against mouse L1210 cells
|
[PMID: 23578545] |
| L1210 | IC50 |
510 nM
Compound: CPT
|
Cytotoxicity against mouse L1210 cells overexpressing folate receptor assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against mouse L1210 cells overexpressing folate receptor assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24901491] |
| L1210 | IC50 |
0.014 μM
Compound: 1
|
Concentration that inhibits the proliferation of L1210 cells by 50%
Concentration that inhibits the proliferation of L1210 cells by 50%
|
[PMID: 2537428] |
| L1210 | IC50 |
14 nM
Compound: 1; CPT
|
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay
Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay
|
[PMID: 38421819] |
| L1210 | ED50 |
2.8 x 10-6 mM
Compound: 1, Camptothecin
|
Cytotoxicity against mouse L1210 cells
Cytotoxicity against mouse L1210 cells
|
[PMID: 423214] |
| L1210 | IC50 |
0.015 μM
Compound: Camptothecin
|
Cytotoxicity was measured on cultured murine lymphoblastic leukemia cells (L1210)
Cytotoxicity was measured on cultured murine lymphoblastic leukemia cells (L1210)
|
[PMID: 8246238] |
| L1210 | IC50 |
0.18 μM
Compound: CPT ((S)-Camptothecin)
|
Cytotoxicity against L1210 tumor cell lines in mice
Cytotoxicity against L1210 tumor cell lines in mice
|
10.1016/0960-894X(96)00131-X |
| L1210 | IC50 |
0.18 μM
Compound: 13 ((S)-CPT, Camptothecin)
|
In vitro cytotoxicity against L1210 mouse leukemia tumor cell line.
In vitro cytotoxicity against L1210 mouse leukemia tumor cell line.
|
10.1016/0960-894X(96)00132-1 |
| L1210 | IC50 |
126 nM
Compound: CPT
|
Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells
Compound was evaluated for cytotoxic activity on L1210 murine leukemia cells
|
10.1016/S0960-894X(97)00398-3 |
| L2987 | IC50 |
0.4 μM
Compound: 1 (CPT)
|
Compound was evaluated for antigen specific activity in vitro L2987 cell line
Compound was evaluated for antigen specific activity in vitro L2987 cell line
|
[PMID: 11755358] |
| L929 | IC50 |
1.132 μM
Compound: CPT
|
Cytotoxicity against mouse L929 cells measured after 72 hrs
Cytotoxicity against mouse L929 cells measured after 72 hrs
|
[PMID: 38716896] |
| LN-229 | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human LN229 cells after 48 hrs by CCK8 assay
Cytotoxicity against human LN229 cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| LNCaP | IC50 |
86.1 nM
Compound: Camptothecin
|
Cytotoxicity against human LNCAP cells by MTT assay
Cytotoxicity against human LNCAP cells by MTT assay
|
[PMID: 11858760] |
| LNCaP | ED50 |
28 nM
Compound: camptothecin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043407] |
| LNCaP | ED50 |
2 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human LNCAP cells by sulforhodamine B assay
Cytotoxicity against human LNCAP cells by sulforhodamine B assay
|
[PMID: 17350834] |
| LNCaP | ED50 |
>10 μM
Compound: Camptothecin
|
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| LoVo | IC50 |
3.1 μM
Compound: CPT
|
Cytotoxicity against human LoVo cells after 3 days by MTT assay
Cytotoxicity against human LoVo cells after 3 days by MTT assay
|
[PMID: 20942490] |
| LoVo | GI50 |
0.008 μM
Compound: 1
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| LoVo | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human LoVo cells after 48 hrs by CCK8 assay
Cytotoxicity against human LoVo cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| LoVo | IC50 |
1.54 μM
Compound: 1; CPT
|
Antiproliferative activity against human LoVo cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| LOX IMVI | IC50 |
48 nM
Compound: 1
|
Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay
|
[PMID: 7853331] |
| Lu1 | IC50 |
28.7 nM
Compound: Camptothecin
|
Cytotoxicity against human Lu1 cells by MTT assay
Cytotoxicity against human Lu1 cells by MTT assay
|
[PMID: 11858760] |
| Lu1 | ED50 |
29 nM
Compound: camptothecin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043407] |
| Lu1 | ED50 |
>10 μM
Compound: Camptothecin
|
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| LX-1 | IC50 |
0.12 μM
Compound: camptothecin
|
Cytotoxicity against human LX1 cells after 72 hrs by MTS method
Cytotoxicity against human LX1 cells after 72 hrs by MTS method
|
[PMID: 11858737] |
| M059J | IC50 |
5.5 μM
Compound: CPT
|
Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay
Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay
|
[PMID: 26649907] |
| Macrophage | IC50 |
0.62 μM
Compound: CPT
|
Cytotoxicity against BALB/C mouse macrophages
Cytotoxicity against BALB/C mouse macrophages
|
[PMID: 22932312] |
| Macrophage | EC50 |
18.32 μM
Compound: CPT
|
Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs infection by propidium iodide staining analysis relative to control
Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs infection by propidium iodide staining analysis relative to control
|
[PMID: 36823782] |
| Mahlavu | IC50 |
<0.1 μM
Compound: CPT
|
Cytotoxicity against human Mahlavu cells after 72 hrs by SRB assay
Cytotoxicity against human Mahlavu cells after 72 hrs by SRB assay
|
[PMID: 22409771] |
| Mahlavu | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| MCF10 | IC50 |
24.77 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF10 cells assessed as reduction in cell viability after 3 hrs by MTT assay
Cytotoxicity against human MCF10 cells assessed as reduction in cell viability after 3 hrs by MTT assay
|
[PMID: 33962153] |
| MCF-10A | IC50 |
0.27 μM
Compound: CPT
|
Cytotoxicity against human MCF10A cells after 2 days
Cytotoxicity against human MCF10A cells after 2 days
|
[PMID: 24904965] |
| MCF-10A | IC50 |
0.97 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay
Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay
|
[PMID: 26361737] |
| MCF-10A | IC50 |
2.19 μM
Compound: 1; CPT
|
Antiproliferative activity against human MCF-10A cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF-10A cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| MCF-10A | IC50 |
2.58 μM
Compound: CPT
|
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36351049] |
| MCF-10A | IC50 |
3.02 μM
Compound: CPT
|
Cytotoxicity against HER-negative human MCF-10A cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against HER-negative human MCF-10A cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 38104378] |
| MCF-12A | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human MCF12A cells after 3 days by SRB assay
Cytotoxicity against human MCF12A cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MCF7 | IC50 |
0.32 μM
Compound: CPT
|
In vitro cytotoxic activity of compound against human MCF-7 cell line
In vitro cytotoxic activity of compound against human MCF-7 cell line
|
[PMID: 15081041] |
| MCF7 | EC50 |
0.072 μM
Compound: camptothecin
|
Cytotoxicity against human MCF7 after 3 days by SRB assay
Cytotoxicity against human MCF7 after 3 days by SRB assay
|
[PMID: 15730238] |
| MCF7 | IC50 |
0.04 μM
Compound: CPT
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 17254669] |
| MCF7 | ED50 |
3.2 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| MCF7 | GI50 |
0.01 μM
Compound: camptothecin
|
Growth inhibition of adriamycin-resistant MCF7 cells after 4 days
Growth inhibition of adriamycin-resistant MCF7 cells after 4 days
|
[PMID: 17418582] |
| MCF7 | GI50 |
0.01 μM
Compound: camptothecin
|
Growth inhibition of MCF7 cells after 4 days
Growth inhibition of MCF7 cells after 4 days
|
[PMID: 17418582] |
| MCF7 | IC50 |
0.2 μM
Compound: 1, CPT
|
Cytotoxicity against human MCF7 cells after 4 days by MTT assay
Cytotoxicity against human MCF7 cells after 4 days by MTT assay
|
[PMID: 18554906] |
| MCF7 | IC50 |
10 μM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 18841903] |
| MCF7 | ED50 |
>10 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| MCF7 | IC50 |
1.22 μM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells by SRB staining-based fluorescence cytometry
Cytotoxicity against human MCF7 cells by SRB staining-based fluorescence cytometry
|
[PMID: 19653666] |
| MCF7 | IC50 |
10 nM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 19655762] |
| MCF7 | IC50 |
3 nM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay
|
[PMID: 19655762] |
| MCF7 | GI50 |
0.01 μM
Compound: 1, CPT
|
Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| MCF7 | IC50 |
1.1 μM
Compound: 1, CPT
|
Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
Cytotoxicity against estrogen receptor-positive human MCF7 cells expressing wild type p53 after 48 hrs by SRB assay
|
[PMID: 19715319] |
| MCF7 | IC50 |
0.06 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
|
[PMID: 19939682] |
| MCF7 | IC50 |
7.42 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 3 days
Cytotoxicity against human MCF7 cells after 3 days
|
[PMID: 19954977] |
| MCF7 | IC50 |
0.02 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 20392545] |
| MCF7 | GI50 |
0.28 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by SRB assay
|
[PMID: 20438092] |
| MCF7 | GI50 |
0.57 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay
|
[PMID: 20591678] |
| MCF7 | IC50 |
14.2 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 4 days by MTT assay
Cytotoxicity against human MCF7 cells after 4 days by MTT assay
|
[PMID: 20619511] |
| MCF7 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 20630766] |
| MCF7 | GI50 |
0.01 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| MCF7 | IC50 |
2.43 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 21115246] |
| MCF7 | IC50 |
0.65 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21186067] |
| MCF7 | GI50 |
6 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| MCF7 | IC50 |
1.6 nM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 21410162] |
| MCF7 | IC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| MCF7 | IC50 |
11.12 μM
Compound: 4
|
Anticancer activity against human MCF7 cells
Anticancer activity against human MCF7 cells
|
[PMID: 21599000] |
| MCF7 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells by SRB assay
Antiproliferative activity against human MCF7 cells by SRB assay
|
[PMID: 21710981] |
| MCF7 | GI50 |
0.013 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| MCF7 | IC50 |
0.056 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 21978950] |
| MCF7 | CC50 |
0.02 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| MCF7 | IC50 |
1.8 μM
Compound: camptothecin
|
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
|
[PMID: 22197145] |
| MCF7 | IC50 |
2.6 μM
Compound: camptothecin
|
Cytotoxicity against human MCF7 cells by WST-1 assay
Cytotoxicity against human MCF7 cells by WST-1 assay
|
[PMID: 22197145] |
| MCF7 | IC50 |
3.91 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 2 days
Cytotoxicity against human MCF7 cells after 2 days
|
[PMID: 22318164] |
| MCF7 | GI50 |
0.013 μM
Compound: 2
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| MCF7 | IC50 |
1.6 nM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 22376176] |
| MCF7 | IC50 |
<0.1 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 22409771] |
| MCF7 | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells incubated for 3 days by SRB assay
Cytotoxicity against human MCF7 cells incubated for 3 days by SRB assay
|
[PMID: 22863526] |
| MCF7 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| MCF7 | CC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| MCF7 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 3 days by SRB assay
Cytotoxicity against human MCF7 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MCF7 | GI50 |
0.002 μM
Compound: Camptothecin
|
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23357037] |
| MCF7 | GI50 |
0.01 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| MCF7 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| MCF7 | IC50 |
3.3 nM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells by SRB assay
Antiproliferative activity against human MCF7 cells by SRB assay
|
[PMID: 24200393] |
| MCF7 | GI50 |
0.013 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 24502276] |
| MCF7 | GI50 |
0.01 μM
Compound: 1
|
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| MCF7 | IC50 |
26 nM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| MCF7 | IC50 |
65.1 nM
Compound: CPT
|
Cytotoxicity against human MCF7 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24901491] |
| MCF7 | IC50 |
<0.024 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 24940955] |
| MCF7 | IC50 |
0.0005 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 25084144] |
| MCF7 | IC50 |
0.003 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay
|
[PMID: 25084144] |
| MCF7 | IC50 |
0.0006 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 25247770] |
| MCF7 | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay
Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay
|
[PMID: 25481396] |
| MCF7 | IC50 |
6 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay
|
[PMID: 26649907] |
| MCF7 | IC50 |
≤0.1 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| MCF7 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 48 hrs
Antiproliferative activity against human MCF7 cells after 48 hrs
|
[PMID: 27070999] |
| MCF7 | IC50 |
4.54 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
|
[PMID: 27654394] |
| MCF7 | IC50 |
<0.0018 μM
Compound: Camptothecin
|
Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 28006904] |
| MCF7 | IC50 |
<0.0018 μM
Compound: Camptothecin
|
Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 28006904] |
| MCF7 | IC50 |
<0.0018 μM
Compound: Camptothecin
|
Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 28006904] |
| MCF7 | IC50 |
71.3 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28063351] |
| MCF7 | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells by SRB assay
Antiproliferative activity against human MCF7 cells by SRB assay
|
[PMID: 28274626] |
| MCF7 | IC50 |
87.5 nM
Compound: 1; CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 28285912] |
| MCF7 | IC50 |
0.073 μM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay
|
[PMID: 28409637] |
| MCF7 | GI50 |
0.013 μM
Compound: 18
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| MCF7 | IC50 |
28.66 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 28462840] |
| MCF7 | GI50 |
0.013 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition
Antiproliferative activity against human MCF7 cells assessed as growth inhibition
|
[PMID: 28657311] |
| MCF7 | IC50 |
13.62 μM
Compound: Camptothecin
|
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382] |
| MCF7 | IC50 |
87.5 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 28927790] |
| MCF7 | IC50 |
0.34 μM
Compound: Camp
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| MCF7 | GI50 |
0.06 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| MCF7 | IC50 |
160 nM
Compound: Camptothecin
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| MCF7 | IC50 |
0.42 μM
Compound: CPT
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| MCF7 | IC50 |
0.04 μM
Compound: CPT
|
Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| MCF7 | IC50 |
0.68 μM
Compound: CPT; 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30509782] |
| MCF7 | IC50 |
0.68 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30600208] |
| MCF7 | IC50 |
2.5 μM
Compound: CPT
|
Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
Poison activity at TOP1 in human MCF7 cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
|
[PMID: 30897325] |
| MCF7 | GI50 |
0.012 μM
Compound: CPT
|
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 31176097] |
| MCF7 | IC50 |
0.03 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| MCF7 | IC50 |
0.084 μM
Compound: CPT
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 32292547] |
| MCF7 | IC50 |
2.8 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CytoX cell viability assay
|
[PMID: 32526552] |
| MCF7 | IC50 |
2.5 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hr by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hr by MTT assay
|
[PMID: 32682183] |
| MCF7 | IC50 |
1.67 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| MCF7 | GI50 |
0.35 μM
Compound: CPT
|
Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF-7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 34008967] |
| MCF7 | GI50 |
3.21 μM
Compound: CPT
|
Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF-7/TDP1 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 34008967] |
| MCF7 | IC50 |
0.56 μM
Compound: 1; CPT
|
Antiproliferative activity against human MCF7 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| MCF7 | IC50 |
0.021 μM
Compound: CPT
|
In-vitro antitumor activity against human MCF7 cells incubated for 72 hrs by CCK8 assay
In-vitro antitumor activity against human MCF7 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 35550978] |
| MCF7 | IC50 |
0.35 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| MCF7 | IC50 |
18.6 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 36996717] |
| MCF7 | IC50 |
6.39 μM
Compound: CPT
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MCF7 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 6 days by SRB assay
|
[PMID: 38107170] |
| MCF7 | IC50 |
6.85 μM
Compound: CPT
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| MCF7 | IC50 |
0.324 μM
Compound: CPT
|
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| MCF7 | GI50 |
1.98 ng/mL
Compound: 1; CPT
|
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 38421819] |
| MCF7 | IC50 |
3.1 nM
Compound: 1; CPT
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38421819] |
| MCF7 | IC50 |
3.1 nM
Compound: CPT
|
Antiproliferative activity measured against MCF-7-mdr cells.
Antiproliferative activity measured against MCF-7-mdr cells.
|
[PMID: 9876111] |
| MCF7 | IC50 |
0.02 μg/mL
Compound: 1
|
Cytotoxicity in MCF-7 cancer cell line
Cytotoxicity in MCF-7 cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| MDA-MB-157 | IC50 |
0.02 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-157 cells after 3 days by SRB assay
Cytotoxicity against human MDA-MB-157 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MDA-MB-231 | IC50 |
0.291 μM
Compound: camptothecin
|
Growth inhibition of human MDA-MB-231 cells by neutral red assay
Growth inhibition of human MDA-MB-231 cells by neutral red assay
|
[PMID: 17204425] |
| MDA-MB-231 | IC50 |
4.16 μM
Compound: camptothecin
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 18178085] |
| MDA-MB-231 | IC50 |
0.68 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 19836231] |
| MDA-MB-231 | IC50 |
1.1 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 3 days
Cytotoxicity against human MDA-MB-231 cells after 3 days
|
[PMID: 19954977] |
| MDA-MB-231 | IC50 |
0.92 μM
Compound: camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 20093033] |
| MDA-MB-231 | IC50 |
0.3 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
|
[PMID: 20392646] |
| MDA-MB-231 | GI50 |
1.3 μM
Compound: Camptothecin
|
Antiproliferative activity against estrogen receptor deficient human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against estrogen receptor deficient human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 20438092] |
| MDA-MB-231 | IC50 |
4.2 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
|
[PMID: 20619511] |
| MDA-MB-231 | IC50 |
0.33 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| MDA-MB-231 | IC50 |
0.97 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 2 days
Cytotoxicity against human MDA-MB-231 cells after 2 days
|
[PMID: 21419530] |
| MDA-MB-231 | IC50 |
2.7 μM
Compound: camptothecin
|
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
|
[PMID: 22197145] |
| MDA-MB-231 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by SRB assay
Cytotoxicity against human MDA-MB-231 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MDA-MB-231 | IC50 |
162 nM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| MDA-MB-231 | IC50 |
0.342 μM
Compound: CPT, Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 24980118] |
| MDA-MB-231 | IC50 |
5.77 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| MDA-MB-231 | IC50 |
8.83 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
|
[PMID: 27707625] |
| MDA-MB-231 | IC50 |
307 nM
Compound: 1; CPT
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 28285912] |
| MDA-MB-231 | IC50 |
307 nM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 28927790] |
| MDA-MB-231 | GI50 |
0.4 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| MDA-MB-231 | IC50 |
540 nM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| MDA-MB-231 | IC50 |
16.44 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| MDA-MB-231 | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human MDA231 cells after 48 hrs by CCK8 assay
Cytotoxicity against human MDA231 cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| MDA-MB-231 | IC50 |
23.98 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
|
[PMID: 31398033] |
| MDA-MB-231 | IC50 |
28.4 nM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 days by [3H]-thymidine incorporation assay
|
[PMID: 32952994] |
| MDA-MB-231 | IC50 |
0.241 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay
|
[PMID: 34052678] |
| MDA-MB-231 | IC50 |
0.17 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34171512] |
| MDA-MB-231 | IC50 |
>6.4 μM
Compound: 1; CPT
|
Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Top1 assessed as cell viability by MTT assay
Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Top1 assessed as cell viability by MTT assay
|
[PMID: 34844412] |
| MDA-MB-231 | IC50 |
0.42 μM
Compound: 1; CPT
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| MDA-MB-231 | IC50 |
264 nM
Compound: 1; CPT
|
Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Ctrl assessed as cell viability by MTT assay
Antiproliferative activity against human MDA-MB-231 cells transfected with siRNA-Ctrl assessed as cell viability by MTT assay
|
[PMID: 34844412] |
| MDA-MB-231 | IC50 |
0.49 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| MDA-MB-231 | IC50 |
1.06 μM
Compound: CPT
|
Cytotoxicity against HER-negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against HER-negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36351049] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 36924947] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MDA-MB-231 | IC50 |
0.53 μM
Compound: CPT
|
Cytotoxicity against HER-negative human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against HER-negative human MDA-MB-231 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 38104378] |
| MDA-MB-231 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 38107170] |
| MDA-MB-231 | IC50 |
0.62 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| MDA-MB-231 | IC50 |
0.108 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| MDA-MB-231 | IC50 |
2.11 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| MDA-MB-361 | IC50 |
0.17 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-361 cells after 3 days by SRB assay
Cytotoxicity against human MDA-MB-361 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MDA-MB-361 | IC50 |
0.17 μM
Compound: Camptothecin
|
Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition
Antitumor activity against human MDA-MB-361 cells assessed as tumor growth inhibition
|
[PMID: 38107170] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line
Antiproliferative activity was determined for 50% growth inhibition against human breast MDA-MB-435 cell line
|
[PMID: 11020283] |
| MDA-MB-435 | IC50 |
15 nM
Compound: camptothecin
|
Inhibition against MDA-MB-435 human breast cancer cells in the absence of HSA
Inhibition against MDA-MB-435 human breast cancer cells in the absence of HSA
|
[PMID: 11052802] |
| MDA-MB-435 | IC50 |
375 nM
Compound: camptothecin
|
Inhibition against MDA-MB-435 human breast cancer cells in the presence of 11 mg/mL HSA
Inhibition against MDA-MB-435 human breast cancer cells in the presence of 11 mg/mL HSA
|
[PMID: 11052802] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 2
|
Growth inhibitory activity against human breast MDA-MB-435 cell line
Growth inhibitory activity against human breast MDA-MB-435 cell line
|
[PMID: 15509164] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: Camptothecin
|
Concentration required to inhibit the growth of human Breast MDA-MB-435 cells
Concentration required to inhibit the growth of human Breast MDA-MB-435 cells
|
[PMID: 16033260] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-435 cell line
Antiproliferative activity against human MDA-MB-435 cell line
|
[PMID: 16442283] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-435 cell line
Antiproliferative activity against human MDA-MB-435 cell line
|
[PMID: 16913702] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human MDA-MB-435 cells
Cytotoxicity against human MDA-MB-435 cells
|
[PMID: 17676830] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 2
|
Cytotoxicity against human MDA-MB-435 cells
Cytotoxicity against human MDA-MB-435 cells
|
[PMID: 17696418] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-435 cells
Antiproliferative activity against human MDA-MB-435 cells
|
[PMID: 18630891] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-435 cells
Cytotoxicity against human MDA-MB-435 cells
|
[PMID: 19783447] |
| MDA-MB-435 | GI50 |
0.04 μM
Compound: 1, CPT
|
Antiproliferative activity against human MDA-MB-435 cells
Antiproliferative activity against human MDA-MB-435 cells
|
[PMID: 20155916] |
| MDA-MB-435 | IC50 |
0.71 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay
|
[PMID: 20942490] |
| MDA-MB-435 | GI50 |
0.033 μM
Compound: 1, CPT
|
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| MDA-MB-435 | IC50 |
0.0436 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay
Antiproliferative activity against human MDA-MB-435 cells after 3 days by MTT assay
|
[PMID: 23084702] |
| MDA-MB-435 | IC50 |
<0.001 μM
Compound: 1, CPT
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
|
[PMID: 24069881] |
| MDA-MB-435 | IC50 |
1 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| MDA-MB-435 | IC50 |
2.7 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| MDA-MB-435 | IC50 |
0.31 μM
Compound: 1; CPT
|
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
|
[PMID: 34844412] |
| MDA-MB-436 | IC50 |
31.86 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
|
[PMID: 31398033] |
| MDA-MB-453 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human MDA-MB-453 cells after 3 days by SRB assay
Cytotoxicity against human MDA-MB-453 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| MDA-MB-453 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-453 cells assessed as reduction in cell growth after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-453 cells assessed as reduction in cell growth after 72 hrs by MTT assay
|
[PMID: 38107170] |
| MDA-MB-468 | IC50 |
14.76 μM
Compound: Camptothecin
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| MDA-MB-468 | IC50 |
1.71 μM
Compound: Camptothecin
|
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
|
[PMID: 27707625] |
| MDA-MB-468 | IC50 |
>100 μM
Compound: CPT
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MEF | IC50 |
5.87 μg/mL
Compound: Camptothecin
|
Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay
Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay
|
[PMID: 25867737] |
| MES-SA | IC50 |
57 nM
Compound: 1a
|
Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay
Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| MES-SA/Dx5 | IC50 |
52 nM
Compound: 1a
|
Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay
Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| MFE-296 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human MFE296 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human MFE296 cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| MG-63 | IC50 |
0.046 μM
Compound: CPT
|
Cytotoxicity against human MG-63 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MG-63 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| MGC-803 | IC50 |
9.45 μM
Compound: Camptothecin
|
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 28462840] |
| MGC-803 | IC50 |
2.96 μM
Compound: CPT
|
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| MGC-803 | IC50 |
4.27 μM
Compound: CPT
|
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30875505] |
| MGC-803 | IC50 |
>150 μM
Compound: CPT
|
Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| MGC-803 | IC50 |
17.76 μM
Compound: Camptothecin
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 36996717] |
| MGC-803 | IC50 |
>100 μM
Compound: CPT
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| MHCC97H | IC50 |
0.32 nM
Compound: Camptothecin
|
Cytotoxicity against human MHCC97H cells after 48 hrs by CCK8 assay
Cytotoxicity against human MHCC97H cells after 48 hrs by CCK8 assay
|
[PMID: 30702286] |
| MIA PaCa-2 | IC50 |
0.4 μM
Compound: Camptothecin
|
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
|
[PMID: 21775156] |
| MIA PaCa-2 | IC50 |
0.19 μM
Compound: Camptothecin
|
Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 24041234] |
| MIA PaCa-2 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281] |
| MIA PaCa-2 | IC50 |
0.18 μM
Compound: CPT
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs in presence of type 1 collagen coated surface by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs in presence of type 1 collagen coated surface by MTT assay
|
[PMID: 28689976] |
| MIA PaCa-2 | IC50 |
0.19 μM
Compound: Camptothecin
|
Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| MKN-45 | IC50 |
17 nM
Compound: CPT
|
In Vitro cytotoxicity against human stomach cancer cell line (MKN45)
In Vitro cytotoxicity against human stomach cancer cell line (MKN45)
|
[PMID: 11334569] |
| MOLT-4 | IC50 |
0.04 nM
Compound: CPT
|
Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay
Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| MRC5 | IC50 |
0.89 μM
Compound: 4
|
Antiproliferative activity against human MRC5 cells
Antiproliferative activity against human MRC5 cells
|
[PMID: 21599000] |
| MRC5 | CC50 |
0.2 μM
Compound: Camptothecin
|
Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| MRC5 | CC50 |
0.2 μM
Compound: Camptothecin
|
Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| MRC5 | IC50 |
1.7 μM
Compound: I; CPT
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 32279049] |
| MRC5 | IC50 |
1.7 x 10-5 μM
Compound: CPT
|
Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
|
[PMID: 33962152] |
| MRC5 | IC50 |
0.8 μM
Compound: CPT
|
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 3 days by resazurin staining based analysis
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 3 days by resazurin staining based analysis
|
[PMID: 34952177] |
| MRC5 | IC50 |
9.02 μM
Compound: Camptothecin
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| MRC5 | IC50 |
>300 μM
Compound: CPT
|
Cytostatic activity against human MRC5 cells after 24 hrs by CCK-8 assay
Cytostatic activity against human MRC5 cells after 24 hrs by CCK-8 assay
|
[PMID: 38278140] |
| MSTO-211H | GI50 |
0.0021 μM
Compound: CPT
|
Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay
Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay
|
[PMID: 27597409] |
| MT4 | IC50 |
0.004 μM
Compound: CPT
|
Antiproliferative activity against human MT4 cells by MTT assay
Antiproliferative activity against human MT4 cells by MTT assay
|
[PMID: 17254669] |
| MT4 | IC50 |
0.004 μM
Compound: Camptothecin
|
Cytotoxicity against human MT4 cells after 96 hrs
Cytotoxicity against human MT4 cells after 96 hrs
|
[PMID: 22276775] |
| MT4 | CC50 |
0.004 μM
Compound: Camptothecin
|
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| MT4 | CC50 |
0.01 μM
Compound: Camptothecin
|
Compound concentration required to reduce the exponential growth of MT-4 cells by 50%
Compound concentration required to reduce the exponential growth of MT-4 cells by 50%
|
[PMID: 9767632] |
| MX1 | IC50 |
1700 nM
Compound: CPT
|
Cytotoxicity against human MX1 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MX1 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24901491] |
| NB-4 | IC50 |
2.01 μM
Compound: Camptothecin
|
Antitumor activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human NB4 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| NCI/ADR-RES | IC50 |
0.8 μM
Compound: camptothecin
|
Cytotoxicity against human MCF7/ADR cells by WST-1 assay
Cytotoxicity against human MCF7/ADR cells by WST-1 assay
|
[PMID: 22197145] |
| NCI-H128 | IC50 |
18 nM
Compound: CPT
|
In Vitro cytotoxicity against human lung cancer cell line (H128)
In Vitro cytotoxicity against human lung cancer cell line (H128)
|
[PMID: 11334569] |
| NCI-H1299 | IC50 |
0.8 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-H1299 cells by MTT assay
Cytotoxicity against human NCI-H1299 cells by MTT assay
|
[PMID: 28506750] |
| NCI-H1299 | IC50 |
>100 μM
Compound: CPT
|
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| NCI-H1299 | IC50 |
3.14 μM
Compound: CPT
|
Antiproliferative activity against human H1299 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human H1299 cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| NCI-H1975 | IC50 |
1.2 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-H1975 cells by MTT assay
Cytotoxicity against human NCI-H1975 cells by MTT assay
|
[PMID: 28506750] |
| NCI-H23 | IC50 |
0.07 μM
Compound: CPT
|
Cytotoxicity against human NCI-H23 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against human NCI-H23 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 27156772] |
| NCI-H446 | IC50 |
>200 μM
Compound: CPT
|
Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| NCI-H446 | IC50 |
>200 μM
Compound: CPT
|
Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| NCI-H460 | IC50 |
0.33 μM
Compound: 1a (Camptothecin)
|
In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line
In vitro cytotoxic activity against human non small cell lung carcinoma H460 cell line
|
[PMID: 11052801] |
| NCI-H460 | EC50 |
0.0069 μM
Compound: camptothecin
|
Cytotoxicity against human H460 after 3 days by SRB assay
Cytotoxicity against human H460 after 3 days by SRB assay
|
[PMID: 15730238] |
| NCI-H460 | IC50 |
0.0062 μM
Compound: 1, CPT
|
Cytotoxicity against human H460 cells after 72 hrs
Cytotoxicity against human H460 cells after 72 hrs
|
[PMID: 18419110] |
| NCI-H460 | IC50 |
0.33 μM
Compound: 1, CPT
|
Cytotoxicity against human H460 cells after 1 hr
Cytotoxicity against human H460 cells after 1 hr
|
[PMID: 18419110] |
| NCI-H460 | IC50 |
0.18 μM
Compound: 1, camptothecin, CPT
|
Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs
Antiproliferative activity against human H460 cells after 1 hr of drug exposure measured after 72 hrs
|
[PMID: 18424133] |
| NCI-H460 | IC50 |
0.33 μM
Compound: 1, CPT
|
Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium
Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium
|
[PMID: 19530720] |
| NCI-H460 | GI50 |
0.03 μM
Compound: CPT
|
Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay
|
[PMID: 20591678] |
| NCI-H460 | IC50 |
>25 μM
Compound: CPT
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 20638158] |
| NCI-H460 | IC50 |
>1000 nM
Compound: 1a
|
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay in presence of 40 mg/ml HSA
|
[PMID: 21341674] |
| NCI-H460 | IC50 |
13 nM
Compound: 1a
|
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
Cytotoxicity against human H460 cells after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| NCI-H460 | IC50 |
<0.04 μM
Compound: Camptothecin
|
Cytotoxicity against human H460 cells after 72 hrs by MTS assay
Cytotoxicity against human H460 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| NCI-H460 | IC50 |
0.03 μM
Compound: 4
|
Anticancer activity against human NCI-H460 cells
Anticancer activity against human NCI-H460 cells
|
[PMID: 21599000] |
| NCI-H460 | IC50 |
5 nM
Compound: Cpt
|
Cytotoxicity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 22749423] |
| NCI-H460 | IC50 |
0.003 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells incubated for 72 hrs by MTT assay
|
[PMID: 22758788] |
| NCI-H460 | IC50 |
0.002 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-H460 cells incubated for 3 days by SRB assay
Cytotoxicity against human NCI-H460 cells incubated for 3 days by SRB assay
|
[PMID: 22863526] |
| NCI-H460 | IC50 |
0.19 μM
Compound: CPT
|
Cytotoxicity against human NCI-H460 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 27156772] |
| NCI-H460 | GI50 |
0.002 μM
Compound: CPT
|
Growth inhibition of human H460 cells after 72 hrs by trypan blue assay
Growth inhibition of human H460 cells after 72 hrs by trypan blue assay
|
[PMID: 27597409] |
| NCI-H460 | GI50 |
0.0057 μM
Compound: Camptothecin
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| NCI-H460 | IC50 |
110 nM
Compound: Camptothecin
|
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29541373] |
| NCI-H460 | IC50 |
5.37 μM
Compound: CPT
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30875505] |
| NCI-H460 | IC50 |
0.12 μM
Compound: CPT
|
Cytotoxicity against human NCI-H460 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 32711231] |
| NCI-H460 | IC50 |
0.79 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| NCI-H520 | IC50 |
25.01 nM
Compound: CPT
|
Cytotoxicity against human NCI-H520 cells assessed as inhibition of cell growth
Cytotoxicity against human NCI-H520 cells assessed as inhibition of cell growth
|
[PMID: 37806498] |
| NCI-H69 | IC50 |
1 nM
Compound: 1a
|
Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay
Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| NCI-H928 | IC50 |
7.8 nM
Compound: 1
|
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human lung carcinoma cells (H928)
Cytotoxicity expressed as the concentration that inhibited incorporation of [3H]-thymidine into cellular DNA of human lung carcinoma cells (H928)
|
[PMID: 10479293] |
| NCI-N87 | IC50 |
0.6 μM
Compound: Camptothecin
|
Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
|
[PMID: 27484510] |
| NCI-N87 | IC50 |
2.32 μM
Compound: CPT
|
Cytotoxicity against HER-positive human NCI-N87 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against HER-positive human NCI-N87 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36351049] |
| NCI-N87 | IC50 |
2.07 μM
Compound: CPT
|
Cytotoxicity against HER-positive human NCI-N87 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against HER-positive human NCI-N87 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 38104378] |
| NHDF | IC50 |
5.38 μM
Compound: Camptothecin
|
Cytotoxicity against HDF cells
Cytotoxicity against HDF cells
|
[PMID: 32932211] |
| NIH3T3 | IC50 |
12 μM
Compound: Camptothecin
|
Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
|
[PMID: 11430001] |
| NIH3T3 | IC50 |
0.086 μM
Compound: CPT
|
Cytotoxicity against mouse NIH3T3 cells measured after 72 hrs
Cytotoxicity against mouse NIH3T3 cells measured after 72 hrs
|
[PMID: 38716896] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line
Antiproliferative activity was determined for 50% growth inhibition against human ovarian OVCAR-3 cell line
|
[PMID: 11020283] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 2
|
Growth inhibitory activity against human ovarian OVCAR-3 cell line
Growth inhibitory activity against human ovarian OVCAR-3 cell line
|
[PMID: 15509164] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Antiproliferative activity against human OVCAR-3 cell line
Antiproliferative activity against human OVCAR-3 cell line
|
[PMID: 16442283] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 2
|
Antiproliferative activity against human OVCAR-3 cell line
Antiproliferative activity against human OVCAR-3 cell line
|
[PMID: 16913702] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 17402722] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 17676830] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 2
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 17696418] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Antiproliferative activity against human OVCAR-3 cells
Antiproliferative activity against human OVCAR-3 cells
|
[PMID: 18630891] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 19783447] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1, CPT
|
Antiproliferative activity against human OVCAR-3 cells
Antiproliferative activity against human OVCAR-3 cells
|
[PMID: 20155916] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 20630766] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Antiproliferative activity against human OVCAR3 cells by SRB assay
Antiproliferative activity against human OVCAR3 cells by SRB assay
|
[PMID: 21710981] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 2
|
Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Cytotoxicity against human OVCAR3 cells by SRB assay
Cytotoxicity against human OVCAR3 cells by SRB assay
|
[PMID: 24502276] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay
Growth inhibition of human OVCAR3 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Antiproliferative activity against human OVCAR3 cells after 48 hrs
Antiproliferative activity against human OVCAR3 cells after 48 hrs
|
[PMID: 27070999] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 18
|
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| OVCAR-3 | GI50 |
0.22 μM
Compound: 1
|
Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition
Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition
|
[PMID: 28657311] |
| P388 | IC50 |
0.032 μM
Compound: CPT
|
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
|
[PMID: 10346933] |
| P388 | IC50 |
13 nM
Compound: Camptothecin
|
Inhibitory activity against P388 murine leukemia cells
Inhibitory activity against P388 murine leukemia cells
|
[PMID: 11384245] |
| P388 | IC50 |
7 nM
Compound: Camptothecin
|
Inhibitory activity against P388 Leukemia cells
Inhibitory activity against P388 Leukemia cells
|
[PMID: 12565975] |
| P388 | IC50 |
13 nM
Compound: Camptothecin
|
Growth inhibitory activity against murine P388 leukemia cells
Growth inhibitory activity against murine P388 leukemia cells
|
[PMID: 12620081] |
| P388 | IC50 |
0.01 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in P388 tumor cell line
Concentration required to inhibit cell proliferation in P388 tumor cell line
|
[PMID: 15482929] |
| P388 | IC50 |
32.1 nM
Compound: camptothecin
|
Cytotoxicity against mouse P388 cells after 72 hrs
Cytotoxicity against mouse P388 cells after 72 hrs
|
[PMID: 17624792] |
| P388 | IC50 |
0.004 nM
Compound: CPT, campothecin
|
Cytotoxicity against human P388 cells
Cytotoxicity against human P388 cells
|
[PMID: 18511275] |
| P388 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay
Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| P388 | IC50 |
0.009 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| P388 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
|
[PMID: 18771930] |
| P388 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells by MTT method
Cytotoxicity against mouse P388 cells by MTT method
|
[PMID: 18771930] |
| P388 | IC50 |
0.014 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells after MTT assay
Cytotoxicity against mouse P388 cells after MTT assay
|
[PMID: 18829334] |
| P388 | IC50 |
0.014 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells by MTT method
Cytotoxicity against mouse P388 cells by MTT method
|
[PMID: 19012996] |
| P388 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| P388 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method
Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method
|
[PMID: 19303306] |
| P388 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against mouse P388 cells after 4 days by MTT method
Cytotoxicity against mouse P388 cells after 4 days by MTT method
|
[PMID: 19303306] |
| P388 | ED50 |
8.6 x 10-6 mM
Compound: 1, Camptothecin
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 423214] |
| P388 | IC50 |
4.74 ng/mL
Compound: 1a
|
Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay
Tested in vitro for the inhibition of P388 (mouse leukemia) cell line by MTT assay
|
[PMID: 7932525] |
| P388 | IC50 |
4.74 ng/mL
Compound: 1
|
In vitro antitumor activity against P388 (murine leukemia) cells.
In vitro antitumor activity against P388 (murine leukemia) cells.
|
[PMID: 9632364] |
| P388 | IC50 |
0.005 μg/mL
Compound: Camptothecin (CPT)
|
Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
|
10.1016/S0960-894X(97)00071-1 |
| P388CPT45 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
|
[PMID: 18829334] |
| P388CPT45 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay
Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| P388CPT5 | IC50 |
2.8 μM
Compound: CPT
|
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
|
[PMID: 10346933] |
| PANC-1 | GI50 |
6.29 μM
Compound: 1, CPT
|
Cytotoxicity against human PANC1 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| PANC-1 | IC50 |
0.09 μM
Compound: CPT
|
Cytotoxicity against human PANC1 cells after 72 hrs by XTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by XTT assay
|
[PMID: 30017114] |
| PANC-1 | IC50 |
0.18 μM
Compound: CPT
|
Cytotoxicity against human PANC1 cells after 48 hrs by XTT assay
Cytotoxicity against human PANC1 cells after 48 hrs by XTT assay
|
[PMID: 30017114] |
| PANC-1 | IC50 |
0.233 μM
Compound: CPT
|
Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| Panel (56 tumour cell lines) | IC50 |
0.04 μM
Compound: 20(S)-Camptothecin
|
Tested in vitro for cytotoxicity against 56 human tumor cell lines
Tested in vitro for cytotoxicity against 56 human tumor cell lines
|
[PMID: 10714502] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
10 nM
Compound: Camptothecin E
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| PBMC | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281] |
| PC-3 | IC50 |
0.31 μM
Compound: CPT
|
In vitro cytotoxic activity of compound against human PC3 cell line
In vitro cytotoxic activity of compound against human PC3 cell line
|
[PMID: 15081041] |
| PC-3 | IC50 |
1414.4 nM
Compound: Camptothecin (table 1)
|
Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line
Concentration required to inhibit growth of human prostate PC-3 carcinoma cell line
|
[PMID: 15454230] |
| PC-3 | IC50 |
52 nM
Compound: camptothecin
|
Antiproliferative activity against human PC3 cell line
Antiproliferative activity against human PC3 cell line
|
[PMID: 16686539] |
| PC-3 | ED50 |
16.7 nM
Compound: 3a, CPT, Camptothecin
|
Cytotoxicity against human PC3 cells by sulforhodamine B assay
Cytotoxicity against human PC3 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| PC-3 | GI50 |
0.09 μM
Compound: 1, camptothecin
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 18180162] |
| PC-3 | GI50 |
0.7 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| PC-3 | IC50 |
1.4 μM
Compound: 1, CPT
|
Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
Cytotoxicity against p53-deficient human PC3 cells after 48 hrs by SRB assay
|
[PMID: 19715319] |
| PC-3 | GI50 |
0.09 μM
Compound: CPT
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| PC-3 | IC50 |
16.24 μM
Compound: CPT
|
Cytotoxicity against human PC3 after 48 hrs by SRB assay
Cytotoxicity against human PC3 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| PC-3 | IC50 |
0.03 μM
Compound: Camptothecin
|
Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay
Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 21074444] |
| PC-3 | GI50 |
0.06 μM
Compound: Camptothecin
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| PC-3 | IC50 |
12 nM
Compound: 1a
|
Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay
Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay
|
[PMID: 21341674] |
| PC-3 | GI50 |
0.48 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| PC-3 | GI50 |
>287 μM
Compound: 1, CPT
|
Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| PC-3 | IC50 |
1.2 μM
Compound: Camptothecin
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 24041234] |
| PC-3 | IC50 |
0.01 μM
Compound: Camptothecin
|
Growth inhibition of human PC3 cells after 72 hrs by MTT assay
Growth inhibition of human PC3 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| PC-3 | IC50 |
78 nM
Compound: CPT
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 24900725] |
| PC-3 | IC50 |
0.1 μM
Compound: CPT
|
Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay
|
[PMID: 25799376] |
| PC-3 | IC50 |
2.5 μM
Compound: CPT
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| PC-3 | IC50 |
6.96 μM
Compound: Camptothecin
|
Antiproliferative activity against human PC3 cells by MTT assay
Antiproliferative activity against human PC3 cells by MTT assay
|
[PMID: 29131616] |
| PC-3 | IC50 |
>40 μM
Compound: Camp
|
Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
|
[PMID: 29223099] |
| PC-3 | IC50 |
0.4 μM
Compound: Camp
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| PC-3 | IC50 |
18.24 μM
Compound: Camptothecin
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| PC-3 | IC50 |
2.4 μM
Compound: CPT
|
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| PC-3 | IC50 |
>100 μM
Compound: CPT
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 37708799] |
| PC-3 | IC50 |
6.6 μM
Compound: CPT
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38154256] |
| PC-3 | IC50 |
0.234 μM
Compound: CPT
|
Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human PC-3 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| PC-3 | IC50 |
57 nM
Compound: CPT
|
Antiproliferative activity measured against PC-3 human prostate adenocarcinoma
Antiproliferative activity measured against PC-3 human prostate adenocarcinoma
|
[PMID: 9876111] |
| PC-3 | IC50 |
1.2 μM
Compound: Camptothecin
|
Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| PC-3M | IC50 |
0.19 μM
Compound: Camptothecin
|
Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method
Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method
|
[PMID: 35696646] |
| PC-3M | IC50 |
0.48 μM
Compound: Camptothecin
|
Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay
Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay
|
[PMID: 35696646] |
| QG-56 | IC50 |
4.63 ng/mL
Compound: 1a
|
Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay
Tested in vitro for the inhibition of QG-56 (human lung squamous cell carcinoma) cell line by MTT assay
|
[PMID: 7932525] |
| QG-56 | IC50 |
4.63 ng/mL
Compound: 1
|
In vitro antitumor activity against QG-56 (human lung cancer) cells.
In vitro antitumor activity against QG-56 (human lung cancer) cells.
|
[PMID: 9632364] |
| Raji | IC50 |
1 μM
Compound: camptothecin
|
Cytotoxicity against human Raji cells by MTT assay
Cytotoxicity against human Raji cells by MTT assay
|
[PMID: 20329739] |
| Raji | IC50 |
3.27 μM
Compound: Camptothecin
|
Cytotoxicity against human Raji cells after 48 hrs by MTT assay
Cytotoxicity against human Raji cells after 48 hrs by MTT assay
|
[PMID: 30109008] |
| RD | IC50 |
4.47 μM
Compound: Camptothecin
|
Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay
Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay
|
[PMID: 23974020] |
| RD | IC50 |
1.24 μM
Compound: CPT
|
Cytotoxicity against human TE32 cells measured after 72 hrs by MTT assay
Cytotoxicity against human TE32 cells measured after 72 hrs by MTT assay
|
[PMID: 27721148] |
| RD | IC50 |
4.49 μM
Compound: Camptothecin
|
Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382] |
| RD | IC50 |
1.24 μM
Compound: CPT
|
Cytotoxicity against human TE32 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human TE32 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28923388] |
| RD | IC50 |
1.72 μM
Compound: CPT
|
Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899] |
| Renca | IC50 |
304 nM
Compound: camptothecin
|
Antiproliferative activity against mouse Renca cell line
Antiproliferative activity against mouse Renca cell line
|
[PMID: 16686539] |
| RKO | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| RKO | IC50 |
0.0617 μM
Compound: CPT
|
Antiproliferative activity against human RKO cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human RKO cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 35868003] |
| RPMI 8402 | IC50 |
0.005 μM
Compound: Camptothecin
|
Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
|
[PMID: 12747798] |
| RPMI 8402 | IC50 |
>10 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant
Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant
|
[PMID: 15482929] |
| RPMI 8402 | IC50 |
0.006 μM
Compound: CPT
|
Concentration required to inhibit cell proliferation in RPM18402 tumor cell line
Concentration required to inhibit cell proliferation in RPM18402 tumor cell line
|
[PMID: 15482929] |
| RPMI 8402 | IC50 |
0.005 μM
Compound: CPT
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| RPMI 8402 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against human RPMI8402 cells by MTT method
Cytotoxicity against human RPMI8402 cells by MTT method
|
[PMID: 18771930] |
| RPMI 8402 | IC50 |
0.006 μM
Compound: CPT
|
Cytotoxicity against human RPMI8402 cells after MTT assay
Cytotoxicity against human RPMI8402 cells after MTT assay
|
[PMID: 18829334] |
| RPMI 8402 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| RPMI 8402 | IC50 |
0.004 μM
Compound: CPT
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT method
Cytotoxicity against human RPMI8402 cells after 4 days by MTT method
|
[PMID: 19303306] |
| RPMI-7951 | IC50 |
0.22 μM
Compound: CPT
|
Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 32435422] |
| RPMI-8226 | IC50 |
0.006 μM
Compound: CPT
|
Cytotoxicity against human RPMI8226 cells by MTT method
Cytotoxicity against human RPMI8226 cells by MTT method
|
[PMID: 19012996] |
| RPMI-8226 | IC50 |
2.05 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
|
[PMID: 25867737] |
| SAOS-2 | GI50 |
>287 μM
Compound: 1, CPT
|
Cytotoxicity against human Saos2 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human Saos2 cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| SAOS-2 | IC50 |
0.055 μM
Compound: CPT
|
Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human SAOS-2 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| SAS | GI50 |
6 μM
Compound: 1, camptothecin
|
Antiproliferative activity against human SAS cells after 48 hrs by MTT assay
Antiproliferative activity against human SAS cells after 48 hrs by MTT assay
|
[PMID: 18180162] |
| SAS | GI50 |
6 μM
Compound: CPT
|
Cytotoxicity against human SAS cells after 48 hrs by MTT assay
Cytotoxicity against human SAS cells after 48 hrs by MTT assay
|
[PMID: 20662543] |
| SAS | IC50 |
6 μM
Compound: CPT
|
Antiproliferative activity against human SAS cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human SAS cells incubated for 72 hrs by MTT assay
|
10.1039/C4MD00133H |
| SF-268 | EC50 |
0.059 μM
Compound: camptothecin
|
Cytotoxicity against human SF-268 after 3 days by SRB assay
Cytotoxicity against human SF-268 after 3 days by SRB assay
|
[PMID: 15730238] |
| SF-268 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human SF268 cell line
Antiproliferative activity against human SF268 cell line
|
[PMID: 16442283] |
| SF-268 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human SF268 cells
Cytotoxicity against human SF268 cells
|
[PMID: 17402722] |
| SF-268 | GI50 |
0.19 μM
Compound: CPT
|
Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
Cytotoxicity against human SF268 cells after 72 hrs by XTT assay
|
[PMID: 20591678] |
| SF-268 | IC50 |
0.04 μM
Compound: Camptothecin
|
Cytotoxicity against human SF268 cells after 72 hrs by MTS assay
Cytotoxicity against human SF268 cells after 72 hrs by MTS assay
|
[PMID: 21513293] |
| SF-268 | IC50 |
0.19 μM
Compound: 4
|
Anticancer activity against human SF268 cells
Anticancer activity against human SF268 cells
|
[PMID: 21599000] |
| SF-268 | IC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human SF268 cells incubated for 3 days by SRB assay
Cytotoxicity against human SF268 cells incubated for 3 days by SRB assay
|
[PMID: 22863526] |
| SF-539 | GI50 |
0.01 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line
Antiproliferative activity was determined for 50% growth inhibition against human CNS SF-539 cell line
|
[PMID: 11020283] |
| SF-539 | GI50 |
0.01 μM
Compound: 2
|
Antiproliferative activity against human SF539 cell line
Antiproliferative activity against human SF539 cell line
|
[PMID: 16913702] |
| SF-539 | GI50 |
0.01 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human SF539 cells
Cytotoxicity against human SF539 cells
|
[PMID: 17676830] |
| SF-539 | GI50 |
0.01 μM
Compound: 2
|
Cytotoxicity against human SF539 cells
Cytotoxicity against human SF539 cells
|
[PMID: 17696418] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human SF539 cells
Antiproliferative activity against human SF539 cells
|
[PMID: 18630891] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human SF539 cells
Cytotoxicity against human SF539 cells
|
[PMID: 19783447] |
| SF-539 | GI50 |
0.01 μM
Compound: 1, CPT
|
Antiproliferative activity against human SF539 cells
Antiproliferative activity against human SF539 cells
|
[PMID: 20155916] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human SF539 cells
Cytotoxicity against human SF539 cells
|
[PMID: 20630766] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human SF539 cells by SRB assay
Antiproliferative activity against human SF539 cells by SRB assay
|
[PMID: 21710981] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| SF-539 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human SF539 cells by SRB assay
Cytotoxicity against human SF539 cells by SRB assay
|
[PMID: 24502276] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Growth inhibition of human SF539 cells after 48 hrs by SRB assay
Growth inhibition of human SF539 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human SF539 cells after 48 hrs
Antiproliferative activity against human SF539 cells after 48 hrs
|
[PMID: 27070999] |
| SF-539 | GI50 |
<0.01 μM
Compound: 18
|
Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
Cytotoxicity against human SF539 cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| SF-539 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human SF539 cells assessed as growth inhibition
Antiproliferative activity against human SF539 cells assessed as growth inhibition
|
[PMID: 28657311] |
| Sf9 | IC50 |
0.025 μM
Compound: CPT
|
Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
Poison activity at recombinant human TOP1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in relaxed supercoiled pBS(SK+) DNA mobility measured after 30 mins by ethidium bromide staining based agarose gel electrophoresis
|
[PMID: 30897325] |
| SGC-7901 | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| SGC-7901 | IC50 |
5.8 μM
Compound: CPT
|
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 35868003] |
| SH-SY5Y | IC50 |
>100 μM
Compound: Camptothecin
|
Growth inhibition of human SH-SY5Y cells after 72 hrs by MTT assay
Growth inhibition of human SH-SY5Y cells after 72 hrs by MTT assay
|
[PMID: 27344492] |
| SH-SY5Y | IC50 |
0.61 μM
Compound: CPT
|
Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499] |
| SiHa | GI50 |
0.55 μM
Compound: Camptothecin
|
Antiproliferative activity against human SiHa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human SiHa cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| SK-BR-3 | IC50 |
20 nM
Compound: CPT
|
In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)
In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3)
|
[PMID: 11334569] |
| SK-BR-3 | GI50 |
0.15 μM
Compound: Camptothecin
|
Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 48 hrs by SRB assay
Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 48 hrs by SRB assay
|
[PMID: 20438092] |
| SK-BR-3 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human SKBR3 cells after 3 days by SRB assay
Cytotoxicity against human SKBR3 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| SK-BR-3 | IC50 |
0.21 μM
Compound: CPT
|
Cytotoxicity against HER-positive human SK-BR-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against HER-positive human SK-BR-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36351049] |
| SK-BR-3 | IC50 |
0.38 μM
Compound: CPT
|
Cytotoxicity against HER-positive human SK-BR-3 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against HER-positive human SK-BR-3 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 38104378] |
| SK-BR-3 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay
|
[PMID: 38107170] |
| SK-HEP1 | IC50 |
0.96 μM
Compound: CPT
|
Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay
Cytotoxicity against human SKHEP1 cells after 72 hrs by MTT assay
|
[PMID: 26226379] |
| SK-HEP1 | IC50 |
0.9 μM
Compound: CPT
|
Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human SKHEP1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31880942] |
| SK-MEL | GI50 |
0.047 μM
Compound: 1
|
Cytotoxicity against human SK-MEL cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| SK-MEL-2 | IC50 |
0.165 μM
Compound: camptothecin
|
Cytotoxicity against human SK-MEL-2 cells after 48 hrs
Cytotoxicity against human SK-MEL-2 cells after 48 hrs
|
[PMID: 17673337] |
| SK-MEL-2 | IC50 |
0.075 μM
Compound: CPT, campothecin
|
Cytotoxicity against human SK-MEL-2 cells by SRB assay
Cytotoxicity against human SK-MEL-2 cells by SRB assay
|
[PMID: 17827007] |
| SK-MEL-2 | IC50 |
6.88 μg/mL
Compound: CPT
|
Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay
|
[PMID: 21684168] |
| SK-MEL-2 | IC50 |
7.86 μM
Compound: CPT
|
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by MTT assay
|
[PMID: 21873069] |
| SK-MEL-24 | IC50 |
0.46 μM
Compound: CPT
|
Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 32435422] |
| SK-MEL-28 | IC50 |
0.04 μM
Compound: CPT
|
Antiproliferative activity against human SK-MEL-28 cells by MTT assay
Antiproliferative activity against human SK-MEL-28 cells by MTT assay
|
[PMID: 17254669] |
| SK-MEL-28 | CC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| SK-MEL-28 | CC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| SK-MEL-28 | IC50 |
<0.01 μM
Compound: Camptothecin
|
Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay
Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| SK-MEL-28 | IC50 |
2.26 μM
Compound: CPT
|
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 35635947] |
| SK-MES-1 | IC50 |
0.01 μM
Compound: CPT
|
Antiproliferative activity against human SKMES1 cells by MTT assay
Antiproliferative activity against human SKMES1 cells by MTT assay
|
[PMID: 17254669] |
| SK-MES-1 | CC50 |
0.03 μM
Compound: Camptothecin
|
Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| SK-MES-1 | CC50 |
0.05 μM
Compound: Camptothecin
|
Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| SK-OV-3 | IC50 |
20 nM
Compound: CPT
|
In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)
In Vitro cytotoxicity against human ovarian cancer cell line (SK-OV-3)
|
[PMID: 11334569] |
| SK-OV-3 | IC50 |
0.014 μM
Compound: camptothecin
|
Cytotoxicity against human SK-OV3 cells after 48 hrs
Cytotoxicity against human SK-OV3 cells after 48 hrs
|
[PMID: 17673337] |
| SK-OV-3 | IC50 |
1.54 μg/mL
Compound: CPT
|
Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
|
[PMID: 21684168] |
| SK-OV-3 | IC50 |
2.544 μM
Compound: CPT
|
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 21873069] |
| SK-OV-3 | IC50 |
5.5 nM
Compound: Camptothecin
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 27017547] |
| SK-OV-3 | IC50 |
5.5 x 10-3 μM
Compound: Camptothecin
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by CCK8 assay
|
[PMID: 27017547] |
| SK-OV-3 | IC50 |
5.5 nM
Compound: CPT
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
|
[PMID: 29501943] |
| SK-OV-3 | IC50 |
5.5 x 10-3 μM
Compound: CPT
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay
|
[PMID: 29501943] |
| SK-OV-3 | IC50 |
5.5 nM
Compound: I; CPT
|
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 31229877] |
| SK-OV-3 | IC50 |
5.5 x 10-3 μM
Compound: I; CPT
|
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 31229877] |
| SK-OV-3 | IC50 |
5.5 μM
Compound: I; CPT
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 32279049] |
| SK-OV-3 | IC50 |
5.5 nM
Compound: CPT
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
|
[PMID: 33962152] |
| SK-OV-3 | IC50 |
5.5 x 10-3 μM
Compound: CPT
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay
|
[PMID: 33962152] |
| SK-OV-3 | IC50 |
5.5 nM
Compound: CPT
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 analysis
|
[PMID: 34952177] |
| SK-OV-3 | IC50 |
3.82 μM
Compound: CPT
|
Cytotoxicity against HER-positive human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against HER-positive human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36351049] |
| SK-OV-3 | IC50 |
2.56 μM
Compound: Camptothecin
|
Antitumor activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| SK-OV-3 | IC50 |
4.86 μM
Compound: Camptothecin
|
Antitumor activity against taxol-resistant human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against taxol-resistant human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| SK-OV-3 | IC50 |
4.07 μM
Compound: CPT
|
Cytotoxicity against HER-positive human SK-OV-3 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against HER-positive human SK-OV-3 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 38104378] |
| SK-OV-3 | IC50 |
0.241 μM
Compound: CPT
|
Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human SK-OV-3 cells incubated for 48 hrs by MTT assay
|
[PMID: 38185054] |
| SK-OV-3 | IC50 |
37 nM
Compound: 1
|
Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay
|
[PMID: 7853331] |
| SK-OV-3 | IC50 |
0.051 μM
Compound: Camptothecin
|
Inhibitory concentration the viability of SKOV 3 cell population by 50%.
Inhibitory concentration the viability of SKOV 3 cell population by 50%.
|
[PMID: 9003520] |
| SK-VLB | IC50 |
41 nM
Compound: 1
|
Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay
|
[PMID: 7853331] |
| SK-VLB | IC50 |
0.053 μM
Compound: Camptothecin
|
Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.
|
[PMID: 9003520] |
| SMMC-7721 | IC50 |
0.02 μM
Compound: CPT
|
Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay
Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| SMMC-7721 | IC50 |
0.003 μM
Compound: camptothecin
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
|
[PMID: 21973054] |
| SMMC-7721 | IC50 |
1.08 μM
Compound: CPT
|
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 30125725] |
| SMMC-7721 | IC50 |
0.45 μM
Compound: CPT; 1
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 30509782] |
| SMMC-7721 | IC50 |
>10 μM
Compound: CPT
|
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34852457] |
| SMMC-7721 | IC50 |
3.95 μM
Compound: Camptothecin
|
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth by SRB assay
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell growth by SRB assay
|
[PMID: 38107170] |
| SN12C | GI50 |
0.02 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line
Antiproliferative activity was determined for 50% growth inhibition against human renal SN12C cell line
|
[PMID: 11020283] |
| SN12C | GI50 |
0.02 μM
Compound: 2
|
Growth inhibitory activity against human renal SN12C cell line
Growth inhibitory activity against human renal SN12C cell line
|
[PMID: 15509164] |
| SN12C | GI50 |
0.02 μM
Compound: Camptothecin
|
Concentration required to inhibit the growth of human Renal SN12C cells
Concentration required to inhibit the growth of human Renal SN12C cells
|
[PMID: 16033260] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Antiproliferative activity against human SN12C cell line
Antiproliferative activity against human SN12C cell line
|
[PMID: 16442283] |
| SN12C | GI50 |
0.02 μM
Compound: 2
|
Antiproliferative activity against human SN12C cell line
Antiproliferative activity against human SN12C cell line
|
[PMID: 16913702] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human SN12C cells
Cytotoxicity against human SN12C cells
|
[PMID: 17402722] |
| SN12C | GI50 |
0.02 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human SN12C cells
Cytotoxicity against human SN12C cells
|
[PMID: 17676830] |
| SN12C | GI50 |
0.02 μM
Compound: 2
|
Cytotoxicity against human SN12C cells
Cytotoxicity against human SN12C cells
|
[PMID: 17696418] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Antiproliferative activity against human SN12C cells
Antiproliferative activity against human SN12C cells
|
[PMID: 18630891] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human SN12C cells
Cytotoxicity against human SN12C cells
|
[PMID: 19783447] |
| SN12C | GI50 |
0.02 μM
Compound: 1, CPT
|
Antiproliferative activity against human SN12C cells
Antiproliferative activity against human SN12C cells
|
[PMID: 20155916] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human SN12C cells
Cytotoxicity against human SN12C cells
|
[PMID: 20630766] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Antiproliferative activity against human SN12C cells by SRB assay
Antiproliferative activity against human SN12C cells by SRB assay
|
[PMID: 21710981] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| SN12C | GI50 |
0.02 μM
Compound: 2
|
Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human SN12C cells by SRB assay
Cytotoxicity against human SN12C cells by SRB assay
|
[PMID: 24502276] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Growth inhibition of human SN12C cells after 48 hrs by SRB assay
Growth inhibition of human SN12C cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Antiproliferative activity against human SN12C cells after 48 hrs
Antiproliferative activity against human SN12C cells after 48 hrs
|
[PMID: 27070999] |
| SN12C | GI50 |
0.02 μM
Compound: 18
|
Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
Cytotoxicity against human SN12C cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| SN12C | GI50 |
0.02 μM
Compound: 1
|
Antiproliferative activity against human SN12C cells assessed as growth inhibition
Antiproliferative activity against human SN12C cells assessed as growth inhibition
|
[PMID: 28657311] |
| SNU-475 | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 26810835] |
| SNU-638 | IC50 |
0.098 μM
Compound: camptothecin
|
Cytotoxicity against human SNU638 cells by SRB assay
Cytotoxicity against human SNU638 cells by SRB assay
|
[PMID: 17498951] |
| SNU-638 | IC50 |
0.098 μM
Compound: 1, CPT
|
Cytotoxicity against human SNU638 cells
Cytotoxicity against human SNU638 cells
|
[PMID: 21095131] |
| SNU-638 | IC50 |
0.098 μM
Compound: CPT
|
Cytotoxicity against human SNU638 cells by MTT assay
Cytotoxicity against human SNU638 cells by MTT assay
|
[PMID: 21353568] |
| SNU-638 | IC50 |
0.28 μM
Compound: Camptothecin
|
Cytotoxicity against human SNU638 cells by MTT assay
Cytotoxicity against human SNU638 cells by MTT assay
|
[PMID: 23608763] |
| Splenocyte | CC50 |
0.62 μM
Compound: CPT
|
Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay
Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay
|
[PMID: 27639365] |
| SU-DHL-2 | IC50 |
0.94 μM
Compound: Camptothecin
|
Antitumor activity against human SUDHL2 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human SUDHL2 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| SW1573 | GI50 |
0.21 μM
Compound: CPT
|
Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| SW1573 | GI50 |
0.25 μM
Compound: Camptothecin
|
Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay
Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay
|
[PMID: 23831507] |
| SW1573 | GI50 |
0.3 μM
Compound: Camptothecin
|
Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
|
[PMID: 37531922] |
| SW1990 | IC50 |
0.2 μM
Compound: CPT
|
Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antitumor activity against human SW1990 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 32668379] |
| SW480 | IC50 |
0.29 μM
Compound: CPT; 1
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 30509782] |
| SW480 | IC50 |
0.21 μM
Compound: Camptothecin
|
Antiproliferation activity against human SW480 cells assessed as reduction in cell viability measured after 72 hours by MTT assay
Antiproliferation activity against human SW480 cells assessed as reduction in cell viability measured after 72 hours by MTT assay
|
[PMID: 32201190] |
| SW480 | IC50 |
8.56 μM
Compound: CPT
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38128233] |
| SW480 | IC50 |
3.75 μM
Compound: Camptothecin
|
Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells
Inhibition of DNA topoisomerase 1 in Homo sapiens (human) SW480 cells
|
10.1007/s00044-009-9233-5 |
| SW480 | IC50 |
0.01 μg/mL
Compound: 1
|
Cytotoxicity in SW480 cancer cell line
Cytotoxicity in SW480 cancer cell line
|
10.1016/S0960-894X(01)80158-X |
| SW-620 | EC50 |
0.15 nM
Compound: Camptothecin
|
Concentration required to inhibit growth of SW620 (human colon cancer) cells in the presence of 10 uM of Compound 2e
Concentration required to inhibit growth of SW620 (human colon cancer) cells in the presence of 10 uM of Compound 2e
|
[PMID: 15857116] |
| SW-620 | EC50 |
1.2 nM
Compound: Camptothecin
|
Concentration required to inhibit growth of SW620 (human colon cancer) cells
Concentration required to inhibit growth of SW620 (human colon cancer) cells
|
[PMID: 15857116] |
| SW-620 | EC50 |
0.0021 μM
Compound: Cpt, camptothecin
|
Antiproliferative activity against human SW620 cells by soft agar assay
Antiproliferative activity against human SW620 cells by soft agar assay
|
[PMID: 17287122] |
| SW626 | IC50 |
28.7 nM
Compound: Camptothecin
|
Cytotoxicity against human SW626 cells by MTT assay
Cytotoxicity against human SW626 cells by MTT assay
|
[PMID: 11858760] |
| SW948 | IC50 |
0.16 μM
Compound: CPT
|
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| T-24 | IC50 |
88 nM
Compound: CPT
|
Cytotoxicity against T24 tumor cell line determined by WST-1 assay
Cytotoxicity against T24 tumor cell line determined by WST-1 assay
|
[PMID: 10841808] |
| T-24 | IC50 |
0.006 μM
Compound: camptothecin
|
Growth inhibition of human T24 cells by neutral red assay
Growth inhibition of human T24 cells by neutral red assay
|
[PMID: 17204425] |
| T-24 | IC50 |
88 nM
Compound: 1, CPT, NSC-100880
|
Cytotoxicity against human chemo-resistant T24 cells by WST assay
Cytotoxicity against human chemo-resistant T24 cells by WST assay
|
[PMID: 23578545] |
| T-24 | IC50 |
6.8 μM
Compound: CPT
|
Antiproliferative activity against human T24 cells after 48 hrs by MTT assay
Antiproliferative activity against human T24 cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| T-24 | IC50 |
3.09 μM
Compound: CPT
|
Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30875505] |
| T47D | GI50 |
1.9 μM
Compound: CPT
|
Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| T47D | GI50 |
2 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells expressing estrogen receptor after 48 hrs by SRB assay
Antiproliferative activity against human T47D cells expressing estrogen receptor after 48 hrs by SRB assay
|
[PMID: 20438092] |
| T47D | IC50 |
1.53 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656] |
| T47D | IC50 |
9.17 μM
Compound: CPT
|
Cytotoxicity against human T47D cells after 72 hrs by MTT assay
Cytotoxicity against human T47D cells after 72 hrs by MTT assay
|
[PMID: 22819942] |
| T47D | IC50 |
<1 μM
Compound: CPT
|
Cytotoxicity against human T47D cells incubated for 72 hrs by SRB assay
Cytotoxicity against human T47D cells incubated for 72 hrs by SRB assay
|
[PMID: 22867707] |
| T47D | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human T47D cells after 3 days by SRB assay
Cytotoxicity against human T47D cells after 3 days by SRB assay
|
[PMID: 23142674] |
| T47D | IC50 |
0.07 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells by MTT assay
Cytotoxicity against human T47D cells by MTT assay
|
[PMID: 23608763] |
| T47D | GI50 |
2 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 48 hrs by SRB assay
Antiproliferative activity against human T47D cells after 48 hrs by SRB assay
|
[PMID: 23831507] |
| T47D | IC50 |
0.3 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 2 days by CCK-8 assay
Cytotoxicity against human T47D cells after 2 days by CCK-8 assay
|
[PMID: 24013413] |
| T47D | IC50 |
0.28 μM
Compound: CPT
|
Cytotoxicity against human T47D cells after 2 days
Cytotoxicity against human T47D cells after 2 days
|
[PMID: 24904965] |
| T47D | IC50 |
0.75 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
|
[PMID: 25062006] |
| T47D | IC50 |
1.84 μM
Compound: camptothecin
|
Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay
Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay
|
[PMID: 25936262] |
| T47D | IC50 |
0.31 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
|
[PMID: 26022080] |
| T47D | IC50 |
1.62 μM
Compound: CPT
|
Cytotoxicity against human T47D cells measured after 2 days by MTT assay
Cytotoxicity against human T47D cells measured after 2 days by MTT assay
|
[PMID: 26334499] |
| T47D | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 2 days by CCK8 assay
Cytotoxicity against human T47D cells after 2 days by CCK8 assay
|
[PMID: 26361737] |
| T47D | IC50 |
11.17 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 3 days by CCK8 assay
Cytotoxicity against human T47D cells after 3 days by CCK8 assay
|
[PMID: 26927425] |
| T47D | IC50 |
1.84 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
|
[PMID: 26945111] |
| T47D | IC50 |
4.1 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
|
[PMID: 26988802] |
| T47D | IC50 |
0.08 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
|
[PMID: 27484510] |
| T47D | IC50 |
13.7 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
|
[PMID: 27643560] |
| T47D | IC50 |
0.59 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
|
[PMID: 27654394] |
| T47D | IC50 |
3.67 μM
Compound: Camptothecin
|
Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
|
[PMID: 27707625] |
| T47D | IC50 |
2.1 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
|
[PMID: 28068603] |
| T47D | IC50 |
2.1 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
|
[PMID: 28384547] |
| T47D | IC50 |
2.31 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
|
[PMID: 28633898] |
| T47D | IC50 |
0.07 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
|
[PMID: 29402741] |
| T47D | IC50 |
0.49 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
|
[PMID: 29510948] |
| T47D | IC50 |
0.07 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
|
[PMID: 30262132] |
| T47D | IC50 |
0.25 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
|
[PMID: 31398033] |
| T47D | IC50 |
0.09 μM
Compound: CPT
|
Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34678573] |
| T47D | GI50 |
2 μM
Compound: Camptothecin
|
Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay
|
[PMID: 37531922] |
| T47D | IC50 |
207 nM
Compound: 1
|
Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay
|
[PMID: 7853331] |
| TERT-RPE1 | ED50 |
230 nM
Compound: camptothecin
|
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
|
[PMID: 15043407] |
| TERT-RPE1 | IC50 |
>40 μM
Compound: Camp
|
Cytotoxicity against human RPE1 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
Cytotoxicity against human RPE1 cells assessed as reduction in cell viability after 48 hrs by ATPlite-based luminescent assay
|
[PMID: 29223099] |
| TERT-RPE1 | IC50 |
27.2 μM
Compound: Camp
|
Induction of apoptosis in human RPE1 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
Induction of apoptosis in human RPE1 cells assessed as caspase 3/7 activity after 24 hrs by caspase-glo luminescent assay
|
[PMID: 29223099] |
| THP-1 | IC50 |
0.6 μM
Compound: 1, CPT
|
Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay
Cytotoxicity against human THP1 cells expressing p53 mutant after 48 hrs by SRB assay
|
[PMID: 19715319] |
| THP-1 | EC50 |
0.16 μM
Compound: camptothecin
|
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
Cytotoxicity against human THP1 cells after 72 hrs by erythosin B staining method
|
[PMID: 20192247] |
| THP-1 | IC50 |
0.071 μM
Compound: Camptothecin
|
Cytotoxicity against human THP1 cells after 2 days by MTT assay
Cytotoxicity against human THP1 cells after 2 days by MTT assay
|
[PMID: 22325897] |
| THP-1 | IC50 |
1.89 μM
Compound: Camptothecin
|
Antitumor activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| Tumor Cell line | GI50 |
44 nM
Compound: camptothecin
|
Mean GI50 against variety of human tumor cell lines
Mean GI50 against variety of human tumor cell lines
|
[PMID: 11052802] |
| U-251 | GI50 |
0.01 μM
Compound: Camptothecin
|
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 48 hrs by sulphorhodamine B assay
|
[PMID: 29313676] |
| U2OS | GI50 |
>287 μM
Compound: 1, CPT
|
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTT assay
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTT assay
|
[PMID: 22867019] |
| U-373MG ATCC | GI50 |
0.033 μM
Compound: 1
|
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
|
[PMID: 21388138] |
| U-373MG ATCC | IC50 |
0.015 μM
Compound: Camptothecin
|
Growth inhibition of human U373 cells after 72 hrs by MTT assay
Growth inhibition of human U373 cells after 72 hrs by MTT assay
|
[PMID: 24180210] |
| U-87MG ATCC | IC50 |
0.5 μM
Compound: Camptothecin
|
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
|
[PMID: 21186067] |
| U-87MG ATCC | IC50 |
0.25 μM
Compound: 21
|
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell viability
|
[PMID: 32858470] |
| U-87MG ATCC | IC50 |
<1.85 μM
Compound: CPT
|
Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| U-937 | IC50 |
0.015 μM
Compound: camptothecin
|
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
0.032 μM
Compound: camptothecin
|
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
0.68 μM
Compound: camptothecin
|
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
0.3 μM
Compound: 1, CPT
|
Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay
Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay
|
[PMID: 19715319] |
| U-937 | IC50 |
1.98 μM
Compound: Camptothecin
|
Cytotoxicity against human U937 cells after 2 days by MTT assay
Cytotoxicity against human U937 cells after 2 days by MTT assay
|
[PMID: 22325897] |
| U-937 | IC50 |
1.81 μM
Compound: Camptothecin
|
Antitumor activity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs
Antitumor activity against human U-937 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 36906964] |
| U-937 | IC50 |
18.24 μM
Compound: Camptothecin
|
Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 36996717] |
| UACC-62 | GI50 |
0.01 μM
Compound: 2 (Camptothecin)
|
Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line
Antiproliferative activity was determined for 50% growth inhibition against human melanoma UACC-62 cell line
|
[PMID: 11020283] |
| UACC-62 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibitory activity against human melanoma UACC-62 cell line
Growth inhibitory activity against human melanoma UACC-62 cell line
|
[PMID: 15509164] |
| UACC-62 | GI50 |
0.01 μM
Compound: Camptothecin
|
Concentration required to inhibit the growth of human Melanoma UACC-62 cells
Concentration required to inhibit the growth of human Melanoma UACC-62 cells
|
[PMID: 16033260] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human UACC62 cell line
Antiproliferative activity against human UACC62 cell line
|
[PMID: 16442283] |
| UACC-62 | GI50 |
0.01 μM
Compound: 2
|
Antiproliferative activity against human UACC62 cell line
Antiproliferative activity against human UACC62 cell line
|
[PMID: 16913702] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human UACC62 cells
Cytotoxicity against human UACC62 cells
|
[PMID: 17402722] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1, Camptothecin
|
Cytotoxicity against human UACC62 cells
Cytotoxicity against human UACC62 cells
|
[PMID: 17676830] |
| UACC-62 | GI50 |
0.01 μM
Compound: 2
|
Cytotoxicity against human UACC62 cells
Cytotoxicity against human UACC62 cells
|
[PMID: 17696418] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human UACC62 cells
Antiproliferative activity against human UACC62 cells
|
[PMID: 18630891] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human UACC62 cells
Cytotoxicity against human UACC62 cells
|
[PMID: 19783447] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1, CPT
|
Antiproliferative activity against human UACC62 cells
Antiproliferative activity against human UACC62 cells
|
[PMID: 20155916] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human UACC62 cells
Cytotoxicity against human UACC62 cells
|
[PMID: 20630766] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human UACC62 cells by SRB assay
Antiproliferative activity against human UACC62 cells by SRB assay
|
[PMID: 21710981] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
|
[PMID: 21823606] |
| UACC-62 | GI50 |
0.01 μM
Compound: 2
|
Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22329436] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human UACC62 cells by SRB assay
Cytotoxicity against human UACC62 cells by SRB assay
|
[PMID: 24502276] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Growth inhibition of human UACC62 cells after 48 hrs by SRB assay
Growth inhibition of human UACC62 cells after 48 hrs by SRB assay
|
[PMID: 24800942] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human UACC62 cells after 48 hrs
Antiproliferative activity against human UACC62 cells after 48 hrs
|
[PMID: 27070999] |
| UACC-62 | GI50 |
<0.01 μM
Compound: 18
|
Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay
|
[PMID: 28418653] |
| UACC-62 | GI50 |
0.01 μM
Compound: 1
|
Antiproliferative activity against human UACC62 cells assessed as growth inhibition
Antiproliferative activity against human UACC62 cells assessed as growth inhibition
|
[PMID: 28657311] |
| Vero | IC50 |
27 μM
Compound: Camptothecin
|
Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form
|
[PMID: 11430001] |
| Vero | IC50 |
0.6 μg/mL
Compound: Camptothecin
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 21985060] |
| Vero | IC50 |
0.02 μg/mL
Compound: camptothecin
|
Cytotoxicity against african green monkey Vero cells after 7 days by XTT assay
Cytotoxicity against african green monkey Vero cells after 7 days by XTT assay
|
[PMID: 8021652] |
| Vero | IC50 |
0.054 μg/mL
Compound: camptothecin
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 8254347] |
| Vero | IC50 |
0.054 μg/mL
Compound: camptothecin
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 9514005] |
| Vero | IC50 |
58 μg/mL
Compound: Camptothecin
|
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by MTT assay
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by MTT assay
|
10.1007/s00044-010-9381-7 |
| WI-38 | IC50 |
0.4 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human WI38 cells by MTT assay
Cytotoxicity against human WI38 cells by MTT assay
|
[PMID: 23816880] |
| WI-38 | IC50 |
0.03 μg/mL
Compound: camptothecin
|
Cytotoxicity against human WI38 cells assessed as cell viability by WST-1 assay
Cytotoxicity against human WI38 cells assessed as cell viability by WST-1 assay
|
[PMID: 24593048] |
| WI-38 | IC50 |
786 nM
Compound: CPT
|
Cytotoxicity against human WI38 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human WI38 cells overexpressing biotin receptor assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24901491] |
| WI-38 | IC50 |
0.23 μM
Compound: Campthotecin
|
Cytotoxicity against human WI38 cells by MTT assay
Cytotoxicity against human WI38 cells by MTT assay
|
[PMID: 26063305] |
| WI-38 | IC50 |
0.03 μM
Compound: Camptothecin
|
Cytotoxicity against human WI38 cells after 48 hrs by WST-1 assay
Cytotoxicity against human WI38 cells after 48 hrs by WST-1 assay
|
[PMID: 28557449] |
| WI-38 | IC50 |
8.37 μM
Compound: CPT
|
Antiproliferative activity against human WI38 cells after 48 hrs by MTT assay
Antiproliferative activity against human WI38 cells after 48 hrs by MTT assay
|
[PMID: 30685528] |
| WiDr | IC50 |
17 nM
Compound: CPT
|
In Vitro cytotoxicity against human colon cancer cell line (WiDr)
In Vitro cytotoxicity against human colon cancer cell line (WiDr)
|
[PMID: 11334569] |
| WiDr | ED50 |
0.07 μg/mL
Compound: Camptothecin
|
Cytotoxicity against human WiDr cells by MTT assay
Cytotoxicity against human WiDr cells by MTT assay
|
[PMID: 18220355] |
| WiDr | IC50 |
0.07 μg/mL
Compound: camptothecin
|
Cytotoxicity against human WiDr cells by MTT assay
Cytotoxicity against human WiDr cells by MTT assay
|
[PMID: 18774864] |
| WiDr | GI50 |
1.7 μM
Compound: CPT
|
Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19664930] |
| WiDr | GI50 |
1.8 μM
Compound: Camptothecin
|
Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay
Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay
|
[PMID: 23831507] |
| WIL2-NS | IC50 |
0.005 μM
Compound: CPT
|
Antiproliferative activity against human WIL-2NS cells by MTT assay
Antiproliferative activity against human WIL-2NS cells by MTT assay
|
[PMID: 17254669] |
| WIL2-NS | CC50 |
0.005 μM
Compound: Camptothecin
|
Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
|
[PMID: 22047799] |
| WIL2-NS | CC50 |
0.005 μM
Compound: Camptothecin
|
Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay
|
[PMID: 22884523] |
| ZR-75-1 | IC50 |
<0.01 μM
Compound: CPT
|
Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay
Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay
|
[PMID: 23142674] |
| ZR-75-30 | IC50 |
0.24 μM
Compound: CPT
|
Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay
Antiproliferative activity against human ZR-7530 cells after 72 hrs by MTT assay
|
[PMID: 28351590] |
High TOP1 enzymatic activity MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) show high sensitivity toward Camptothecin (0.1 μM to 5 μM; 72 hours) treatment, exhibiting the IC50 values of 0.089 μM and 0.067 μM, respectively[4].
Camptothecin (0.5 μM; 6 and 24 hours) reduces desferrioxamine-activated VEGF expression.
Camptothecin (0.5 μM; 8 to 24 hours) strongly prevents the desferrioxamine-dependent HIF-1a accumulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7 (Luminal subtype) and HCC1419 (HER2 subtype)
-
Concentration:0.1 μM to 5 μM
-
Incubation Time:72 hours
-
Result:High TOP1 enzymatic activity MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) show high sensitivity toward CPT (0.1 μM to 5 μM; 72 hours) treatment, exhibiting the IC50 values of 0.089 μM and 0.067 μM, respectively.
-
Cell Line:HeLa and HEK293 cell lines
-
Concentration:0.5 μmol/L
-
Incubation Time:6 and 24 hours
-
Result:Reduces desferrioxamine-activated VEGF expression in both cell lines after 6 and 24 hours of treatment, whereas in normoxic condition camptothecin does not affect the VEGF mRNA level.
-
Cell Line:HeLa and HEK293 cell lines
-
Concentration:0.5 μmol/L
-
Incubation Time:8 to 24 hours
-
Result:Strongly prevents the desferrioxamine-dependent HIF-1a accumulation after 8 to 24 hours, whereas it does not affect HIF-1b levels.
Treatment with both kinase inhibitor of nuclear factor-kappaB-1 (KINK-1) and Camptothecin led to a statistically significant reduction in the number of pulmonary metastases[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL6 mice (injected with B16F10 melanoma cells)[5]
-
Dosage:2 mg/kg
-
Administration:every other day, after 19 days
-
Result:Has developed numerous pulmonary metastases.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 7689-03-4
-
Appearance Solid
-
Molecular Weight 348.35
-
Formula C20H16N2O4
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5
-
Synonyms
Campathecin; (S)-(+)-Camptothecin; CPT
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications (68)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Cancer Cell
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. [Abstract]2025 Feb 10;43(2):269-291.e19. PMID: 39933899 -
Cell
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601 -
Mol Cancer
ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma. [Abstract]2025 Oct 21;24(1):263. PMID: 41121283 -
Nat Immunol
2024 Apr;25(4):659-670. PMID: 38499799 -
Immunity
Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling. [Abstract]2022 Aug 9;55(8):1370-1385.e8. PMID: 35835107 -
Mol Cell
Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721 -
Cancer Res
SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]2025 May 14. PMID: 40366633 -
ACS Nano
Coassembly Nanomedicine Mediated by Intermolecular Interactions Between Methotrexate and Baricitinib for Improved Rheumatoid Arthritis Treatment. [Abstract]2024 Mar 19;18(11):8337-8349. PMID: 38437640 -
Nat Commun
Oxidative phosphorylation is a key feature of neonatal monocyte immunometabolism promoting myeloid differentiation after birth. [Abstract]2025 Mar 6;16(1):2239. PMID: 40050264 -
Nat Commun
2024 Sep 27;15(1):8283. PMID: 39333491 -
Nat Commun
Transcription-independent regulation of STING activation and innate immune responses by IRF8 in monocytes. [Abstract]2022 Aug 16;13(1):4822. PMID: 35973990 -
Nat Commun
Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. [Abstract]2021 Aug 16;12(1):4961. PMID: 34400640 -
Nat Commun
Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]2019 Aug 21;10(1):3761. PMID: 31434880
Camptothecin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.
-
Nat Commun
ATR/Chk1 signaling induces autophagy through sumoylated RhoB-mediated lysosomal translocation of TSC2 after DNA damage. [Abstract]2018 Oct 8;9(1):4139. PMID: 30297842
Camptothecin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]
One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.
-
Cell Death Differ
TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. [Abstract]2025 Jul;32(7):1317-1335. PMID: 40133668 -
Cell Death Differ
Angiopoietin-like protein 8 directs DNA damage responses towards apoptosis by stabilizing PARP1-DNA condensates. [Abstract]2025 Apr;32(4):672-688. PMID: 39592710 -
Cell Death Differ
2020 Nov;27(11):3162-3176. PMID: 32494026
Camptothecin purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2020 Nov;27(11):3162-3176. [Abstract]
293T cells transfected with Flag-TopBP1 and GFP-tagged RBMX and its domain (RRM, RBM1CTR, and C-RBD) are treated with 100 nM CPT for 24 h and subjected to immunoprecipitation with Flag-beads. Immunoprecipitates are immunoblotted with Flag and GFP antibodies, respectively.
-
Autophagy
2021 Dec;17(12):3976-3991. PMID: 33752561 -
Adv Sci (Weinh)
Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Binary System. [Abstract]2026 Apr;13(23):e11485. PMID: 41671402 -
Cancer Lett
ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. [Abstract]2022 Oct 28:547:215855. PMID: 35998796 -
Int J Biol Sci
2015 Aug 8;11(10):1181-9. PMID: 26327812 -
Gene Dis
2019 May 25;7(3):401-407. PMID: 32884994 -
Proc Natl Acad Sci U S A
The RPA-RNF20-SNF2H cascade promotes proper chromosome segregation and homologous recombination repair. [Abstract]2023 May 16;120(20):e2303479120. PMID: 37155876 -
J Transl Med
Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. [Abstract]2016 Mar 15:14:73. PMID: 26980293 -
Oncogene
BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance. [Abstract]2023 Mar;42(13):967-979. PMID: 36725890 -
PLoS Biol
2022 Feb 24;20(2):e3001517. PMID: 35202387 -
Cell Rep
53BP1 regulates p53-E2F7-dependent transcriptional gene repression and participates in the Fanconi anemia pathway. [Abstract]2025 Aug 12;44(8):116152. PMID: 40811062 -
Cell Rep
The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability. [Abstract]2024 Feb 13;43(2):113779. PMID: 38358891 -
J Med Chem
Modular Synthesis of Bioactive Selenoheterocycles for Efficient Cancer Therapy via Electrochemical Selenylation/Cyclization. [Abstract]2025 Mar 27;68(6):6339-6360. PMID: 40063343 -
J Cell Biol
2026 Jan 5;225(1):e202501091. PMID: 41335120 -
Int J Mol Med
2019 Jun;43(6):2491-2498. PMID: 31017265 -
Cells
2019 Oct 15;8(10):1258. PMID: 31619012 -
Int J Mol Sci
Novel Camptothecin Derivative 9c with Enhanced Antitumor Activity via NSA2-EGFR-P53 Signaling Pathway. [Abstract]2025 Feb 25;26(5):1987. PMID: 40076615 -
Int Immunopharmacol
Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms. [Abstract]2026 Jan 31:173:116284. PMID: 41621382 -
Eur J Pharmacol
Targeting Skp2 by camptothecin induces p27 accumulation and confers drug resistance in non-small cell lung cancer. [Abstract]2026 Jan 12:1011:178422. PMID: 41344534 -
Front Endocrinol
2022 Jun 16:13:912648. PMID: 35784529 -
Cancers (Basel)
In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]2023 Sep 6;15(18):4442. PMID: 37760412 -
FASEB J
Targeting EME1 Increases the Sensitivity of Camptothecin in Nasopharyngeal Carcinoma Cells. [Abstract]2026 Jan 31;40(2):e71434. PMID: 41532283 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Transl Oncol
FOSL1 promotes homologous recombination repair and camptothecin resistance via TCOF1-mediated ribosome biogenesis in non-small cell lung cancer. [Abstract]2026 Apr:66:102701. PMID: 41687404 -
J Inflamm Res
2025 Mar 20:18:4213-4231. PMID: 40129872 -
J Cell Physiol
Genistein-induced DNA damage is repaired by nonhomologous end joining and homologous recombination in TK6 cells. [Abstract]2019 Mar;234(3):2683-2692. PMID: 30070703 -
PLoS Genet
Strand break-induced replication fork collapse leads to C-circles, C-overhangs and telomeric recombination. [Abstract]2019 Feb 4;15(2):e1007925. PMID: 30716077 -
Exp Cell Res
Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma. [Abstract]2020 Sep 15;394(2):112148. PMID: 32585151 -
BMC Cancer
The Hippo pathway promotes platinum-based chemotherapy by inhibiting MTF1-dependent heavy metal response. [Abstract]2025 Feb 8;25(1):223. PMID: 39920630 -
BMC Cancer
2024 Mar 9;24(1):326. PMID: 38461240 -
Cell Biol Int
Critical roles of tyrosyl-DNA phosphodiesterases in cell tolerance to carnosol-induced DNA damage. [Abstract]2020 Aug;44(8):1640-1650. PMID: 32301547 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Toxicol In Vitro
Nonhomologous end joining and homologous recombination involved in luteolin-induced DNA damage in DT40 cells. [Abstract]2020 Jun;65:104825. PMID: 32169435 -
Toxicol In Vitro
2017 Aug:42:130-138. PMID: 28431926 -
J Hum Genet
Homozygous synonymous FAM111A variant underlies an autosomal recessive form of Kenny-Caffey syndrome. [Abstract]2025 Feb;70(2):87-97. PMID: 39501122 -
Exp Ther Med
2021 May;21(5):505. PMID: 33791014 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
Biomed Chromatogr
Quantitative Analysis of the Active Metabolite of VX-150 Using UPLC-MS/MS: A Preclinical Pharmacokinetic Study in Rats. [Abstract]2025 Nov;39(11):e70237. PMID: 41084234 -
Biosci Biotechnol Biochem
The fission yeast bromodomain protein Bdf2 is required for the growth of cells with circular chromosomes. [Abstract]2022 Jan 24;86(2):224-230. PMID: 34918022 -
-
-
-
-
bioRxiv
The TONSL-MMS22L complex and FANCM form an interdependent complex on chromatin to counter replication stress. [Abstract]2025 Mar 10:2025.03.07.642025. PMID: 41030968 -
bioRxiv
2024 Sep 24:2024.09.23.614588. PMID: 39386652 -
bioRxiv
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. [Abstract]2023 Sep 28:2023.09.28.559973. PMID: 37808840 -
Camptothecin purchased from MedChemExpress. Usage Cited in: Arch Cancer Res. 2023 Jan 30.
Camptothecin (CPT; 10-5 -10-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC50 = 25.36 nM) in U937 cells.
-
-
-
-
Solvent & Solubility
1M NaOH : 10 mg/mL (28.71 mM; ultrasonic and adjust pH to 11 with NaOH)
DMSO : 6.25 mg/mL (17.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (28.71 mM); Suspended solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Luzzio MJ, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. [Content Brief]
[2]. Bertozzi D, et al. The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther. 2014;13(1):239-248. [Content Brief]
[3]. Huang Q, et al. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. Eur J Med Chem. 2013;63:746-757. [Content Brief]
[4]. Tesauro C, et al. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. BMC Cancer. 2019;19(1):1158. Published 2019 Nov 29. [Content Brief]
[5]. Schön M, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst. 2008;100(12):862-875.. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 1M NaOH | 1 mM | 2.8707 mL | 14.3534 mL | 28.7068 mL | 71.7669 mL |
| 5 mM | 0.5741 mL | 2.8707 mL | 5.7414 mL | 14.3534 mL | |
| 10 mM | 0.2871 mL | 1.4353 mL | 2.8707 mL | 7.1767 mL | |
| 15 mM | 0.1914 mL | 0.9569 mL | 1.9138 mL | 4.7845 mL | |
| 1M NaOH | 20 mM | 0.1435 mL | 0.7177 mL | 1.4353 mL | 3.5883 mL |
| 25 mM | 0.1148 mL | 0.5741 mL | 1.1483 mL | 2.8707 mL |